WO2024085558A1 - Composition for preventing or treating oscar-induced diseases, containing brivudin as active ingredient - Google Patents

Composition for preventing or treating oscar-induced diseases, containing brivudin as active ingredient Download PDF

Info

Publication number
WO2024085558A1
WO2024085558A1 PCT/KR2023/015909 KR2023015909W WO2024085558A1 WO 2024085558 A1 WO2024085558 A1 WO 2024085558A1 KR 2023015909 W KR2023015909 W KR 2023015909W WO 2024085558 A1 WO2024085558 A1 WO 2024085558A1
Authority
WO
WIPO (PCT)
Prior art keywords
oscar
composition
pharmaceutical composition
cartilage
present
Prior art date
Application number
PCT/KR2023/015909
Other languages
French (fr)
Korean (ko)
Inventor
김완규
박세라
이수영
김지희
Original Assignee
주식회사 카이팜
이화여자대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 카이팜, 이화여자대학교 산학협력단 filed Critical 주식회사 카이팜
Publication of WO2024085558A1 publication Critical patent/WO2024085558A1/en

Links

Images

Definitions

  • the present invention relates to a composition for preventing or treating osteoclast-associated Ig-like receptor (OSCAR)-induced diseases containing brivudine as an active ingredient.
  • OSCAR osteoclast-associated Ig-like receptor
  • OSCAR osteoclast-associated Ig-like receptor
  • OSCAR is a cell surface receptor with two immunoglobulin domains that belongs to the leukocyte receptor complex.
  • Oscar regulates osteoclast differentiation through osteoclast-specific expression. This differentiation of osteoclasts is regulated through the interaction between osteoclasts and osteoblasts. During this process, osteoblasts secrete collagen outside the cells, and the secreted collagen functions as a ligand for Oscar.
  • substances that have the activity of inhibiting the mutual binding of collagen and Oscar can inhibit the activity of Oscar. These substances can be used as inhibitors of diseases induced by collagen-Oscar binding.
  • OSCAR-induced diseases include various cancers including bladder cancer, breast cancer, cholangiocarcinoma, colon adenocarcinoma, esophageal cancer, head and neck cancer, renal induced cell carcinoma, rectal adenocarcinoma, gastric adenocarcinoma, and thyroid carcinoma, hypertension, periodontal disease, and bone cancer.
  • Metabolic diseases, rheumatoid arthritis, chronic obstructive pulmonary disease, emphysema, pneumonia, tuberculosis, cardiovascular diseases, atherosclerosis, diabetes, etc. are known.
  • OSCAR is highly expressed in the above diseases, and OSCAR levels are associated with the severity of the disease.
  • Bribudin has the structural formula of Formula 1, and its compound name is (E)-5-(2-bromovinyl)-2'-deoxyuridine.
  • Bribudin is an analogue of the nucleoside thymidine, and the active compound is brivudin 5'-triphosphate, which is formed by phosphorylation by viral thymidine kinase. Bribudin is quickly absorbed from the intestines and undergoes first metabolism in the liver, and the enzyme thymidine phosphorylase quickly decomposes the sugar component, leading to a bioavailability of 30%.
  • the present inventors studied compounds that inhibit or bind to Oscar based on artificial intelligence or big data analysis, which are drug information search methods based on compound activity data. As a result, brivudine controls Oscar signaling and shows that OSCAR mRNA
  • the present invention was completed by confirming the treatment effect of OSCAR-induced diseases, including bone metabolic diseases, by alleviating inflammation and promoting differentiation and regeneration of chondrocytes as an OSCAR inhibitor that reduces expression.
  • the object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of osteoclast-associated Ig-like receptor (OSCAR)-induced diseases, comprising brivudine or a pharmaceutically acceptable salt thereof as an active ingredient.
  • OSCAR osteoclast-associated Ig-like receptor
  • Another object of the present invention is to provide a method of treating OSCAR-induced disease, comprising administering the pharmaceutical composition to a subject suspected of having OSCAR (osteoclast-associated Ig-like receptor; OSCAR)-induced disease.
  • OSCAR osteoclast-associated Ig-like receptor
  • Another object of the present invention is to provide a use of brivudine or a pharmaceutically acceptable salt thereof for the prevention and treatment of osteoclast-associated Ig-like receptor (OSCAR)-induced diseases.
  • OSCAR osteoclast-associated Ig-like receptor
  • Another object of the present invention is to provide the use of brivudine or a pharmaceutically acceptable salt thereof for manufacturing a therapeutic agent for oskar-induced diseases.
  • Another object of the present invention is to provide an osteoclast-associated Ig-like receptor (OSCAR) inhibitor containing brivudine or a pharmaceutically acceptable salt thereof as an active ingredient.
  • OSCAR osteoclast-associated Ig-like receptor
  • Another object of the present invention is to provide a method for inhibiting osteoclast-associated Ig-like receptor (OSCAR) comprising brivudine or a pharmaceutically acceptable salt thereof as an active ingredient.
  • OSCAR osteoclast-associated Ig-like receptor
  • Another object of the present invention is to provide a food composition for preventing or improving osteoclast-associated Ig-like receptor (OSCAR)-induced diseases, comprising brivudine or a food-acceptable salt thereof as an active ingredient. It is done.
  • OSCAR osteoclast-associated Ig-like receptor
  • Another object of the present invention is to provide a quasi-drug composition for preventing or improving osteoclast-associated Ig-like receptor (OSCAR)-induced diseases, comprising brivudine or a pharmaceutically acceptable salt thereof as an active ingredient. It is done.
  • OSCAR osteoclast-associated Ig-like receptor
  • Another object of the present invention is to provide a feed additive composition for preventing or improving osteoclast-associated Ig-like receptor (OSCAR)-induced diseases, which contains brivudine or a feedwise acceptable salt thereof as an active ingredient. It is provided.
  • OSCAR osteoclast-associated Ig-like receptor
  • the present invention provides a pharmaceutical composition for the prevention or treatment of osteoclast-associated Ig-like receptor (OSCAR)-induced diseases comprising brivudine or a pharmaceutically acceptable salt thereof represented by the following formula (1) as an active ingredient. provides.
  • OSCAR osteoclast-associated Ig-like receptor
  • the present invention provides brivudin or a pharmaceutically acceptable salt thereof represented by Formula 1 for use in the treatment of oskar-induced diseases.
  • the present invention provides the use of brivudin or a pharmaceutically acceptable salt thereof represented by Formula 1 for manufacturing a therapeutic agent for oskar-induced diseases.
  • the compound name of brivudine of the present invention is also referred to as (E)-5-(2-bromovinyl)-2'-deoxyuridine.
  • the brivudine is useful as an antiviral treatment known to be used in the treatment of shingles, and acts by inhibiting replication of the target virus.
  • Bribudin has the structural formula of Chemical Formula 1 above.
  • Bribudin is an analogue of the nucleoside thymidine, and the active compound is brivudin 5'-triphosphate, which is formed by phosphorylation by viral thymidine kinase. Bribudin is quickly absorbed from the intestines and undergoes first metabolism in the liver, and the enzyme thymidine phosphorylase quickly decomposes the sugar component, leading to a bioavailability of 30%.
  • an acid addition salt formed by a free acid is useful.
  • Acid addition salts are prepared by conventional methods, for example, by dissolving the compound in an excess of aqueous acid and precipitating the salt using a water-miscible organic solvent such as methanol, ethanol, acetone, or acetonitrile. Equimolar amounts of the compound and an acid or alcohol (e.g., glycol monomethyl ether) in water can be heated and the mixture then evaporated to dryness, or the precipitated salt can be filtered off with suction.
  • an acid or alcohol e.g., glycol monomethyl ether
  • organic acids and inorganic acids can be used as free acids.
  • Hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, tartaric acid, etc. can be used as inorganic acids, and methanesulfonic acid, p-toluenesulfonic acid, acetic acid, and trifluoroacetic acid can be used as organic acids.
  • a pharmaceutically acceptable metal salt can be prepared using a base.
  • the alkali metal or alkaline earth metal salt is obtained, for example, by dissolving the compound in an excess of alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and then evaporating and drying the filtrate.
  • it is particularly pharmaceutically suitable to prepare sodium, potassium or calcium salts as metal salts, and the corresponding silver salts are obtained by reacting an alkali metal or alkaline earth metal salt with an appropriate silver salt (eg, silver nitrate).
  • Pharmaceutically acceptable salts of the compounds of the invention include salts of acidic or basic groups that may be present in the compounds of the invention.
  • pharmaceutically acceptable salts include sodium, calcium, and potassium salts of hydroxy groups
  • other pharmaceutically acceptable salts of amino groups include hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, and dihydrogen.
  • phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulfonate (mesylate), and p-toluenesulfonate (tosylate) salts and methods or processes for producing salts known in the art. It can be manufactured through.
  • the osteoclast-associated Ig-like receptor (OSCAR)-induced disease of the present invention may include, but is not limited to, cancer, hypertension, bone metabolic disease, chronic inflammatory lung disease, cardiovascular disease, atherosclerosis, or diabetes.
  • the bone metabolic disease of the present invention may be osteoporosis, arthritis, periodontal disease, fracture, or Paget's disease, and the arthritis may be osteoarthritis or rheumatoid arthritis, but is not limited thereto.
  • Bone metabolic disease of the present invention refers to a bone-related disease caused by an imbalance between osteoblasts and osteoclasts.
  • the bone metabolic diseases include bone destruction due to pathological bone diseases such as osteoporosis, arthritis, periodontal disease, fractures, or Paget disease caused by excessive bone resorption by osteoclasts. Diseases that promote, but are not limited to, are included.
  • the osteoporosis refers to a condition in which bone strength is weakened due to a decrease in bone quantity and qualitative changes, making fractures more likely to occur. Bone protects various organs in the human body, functions as a storage site for substances necessary for the body, such as calcium, and maintains homeostasis through the balance between osteoclasts that break down bone present in bone tissue and osteoblasts that produce bone. do. In the case of osteoporosis, the activity of two cells becomes unbalanced and excessive bone destruction by osteoclasts occurs, causing the disease to develop and progress.
  • the arthritis refers to a joint disease accompanied by inflammation in one or more joint areas.
  • the common form of arthritis is osteoarthritis, in which inflammation and pain occur due to damage to the bones and ligaments forming the joint due to gradual damage or degenerative changes in the cartilage that protects the joint.
  • Arthritis of the present invention is a disease accompanied by bone loss in the joint area, and the type is not particularly limited, but may be osteoarthritis or rheumatoid arthritis.
  • Osteoarthritis of the present invention also called degenerative arthritis, is a chronic disease in which damage to the bones, cartilage, and ligaments that form joints occurs due to damage or degenerative changes in cartilage, causing inflammation and pain. Osteoarthritis occurs in almost all joints in the body, including fingers, knees, hips, lower back, and neck. The main symptoms of osteoarthritis are repetitive pain, joint stiffness, decreased mobility, and loss of function. The clinical course usually progresses slowly, and as the disease progresses to a certain extent, the joint surface becomes irregular due to loss and degeneration of the articular cartilage, causing severe pain, and gradual movement disorders, which greatly interfere with daily life. Deformation also occurs.
  • Chondrocyte death is regulated downstream of the OSCAR receptor by the regulation of TRAIL and OPG. Collagen degradation due to shock and aging can activate OSCAR on the surface of chondrocyte cells in the extracellular matrix, thereby inducing cell death of chondrocyte cells.
  • OSCAR a cell membrane surface receptor of chondrocytes, plays an important role in controlling cartilage degeneration, this means that osteoarthritis can be caused by OSCAR.
  • Soluble OSCAR levels in rheumatoid arthritis are also related to the severity of the disease and the risk of cardiovascular disease.
  • OSCAR-collagen signaling in monocytes plays a pro-inflammatory role and may contribute to the pathogenesis of rheumatoid arthritis.
  • the periodontal disease refers to an inflammatory condition of the tooth-supporting tissue caused by bacteria, and can be divided into gingivitis and periodontitis.
  • the cause of the disease is oral bacteria forming a bacterial film on the teeth due to poor oral hygiene.
  • Dental biofilm refers to a mass of bacteria that grows after sticking to the tooth surface using the sticky substance in saliva as an adhesive. If the bacterial film on the teeth is left untreated, it can become inflamed, causing gums to bleed and bad breath. These symptoms are called gingivitis. As gingivitis progresses further, the gaps between the teeth and gums become deeper, forming periodontal pockets, and the bacteria that cause periodontal disease multiply here, causing periodontitis.
  • the fracture refers to a state in which the continuity of the bone, epiphyseal plate, or joint surface is abnormally broken, and refers to the breakage of the bone.
  • causes of fractures include trauma such as traffic accidents, industrial accidents, bone changes due to diseases such as osteoporosis, bone cancer, and metabolic disorders, and repetitive stress on the bones due to sports or load.
  • fracture conditions can be classified into crack fractures, greenstick fractures, transverse fractures, filiform fractures, spiral fractures, segmental fractures, comminuted fractures, avulsion fractures, compression fractures, depressed fractures, etc.
  • Paget's disease refers to a localized bone disease in which bone remodeling is excessively promoted and a wide area of the skeletal system is invaded.
  • the pathological mechanism of Paget's disease is known to be a combination of an excessive increase in bone resorption by osteoclasts, which have the function of cleaning bones, and an increase in new bone formation by osteoblasts, which have the function of making bones as a compensation.
  • the newly formed bone in Paget's disease of bone is known to be structurally disordered and very vulnerable to bone deformation and fracture.
  • the pharmaceutical composition containing brivudin or a pharmaceutically acceptable salt thereof of the present invention as an active ingredient has oscar inhibitory activity, promotes differentiation of chondrocytes, Since it shows cartilage regeneration activity even after cartilage degeneration, it can have a preventive or therapeutic effect on the above diseases.
  • the cancer of the present invention may be bladder cancer, breast cancer, cholangiocarcinoma, colon adenocarcinoma, esophageal cancer, head and neck cancer, renal induced cell carcinoma, rectal adenocarcinoma, gastric adenocarcinoma, or thyroid carcinoma, but is not limited thereto.
  • OSCAR can promote malignancy in several cancer types, with enhanced metastasis associated with a suppressive immune microenvironment. The group with high OSCAR had a statistically significantly higher metastatic status. High expression of OSCAR is significantly associated with poor prognosis for many carcinomas, serving as a biomarker when considered together with a suppressive immune microenvironment.
  • the pharmaceutical composition containing brivudin or a pharmaceutically acceptable salt thereof of the present invention as an active ingredient has oscar inhibitory activity, and thus prevents or treats the above carcinomas. It can have a therapeutic effect.
  • Hypertension of the present invention refers to an abnormally elevated state of blood pressure, and in specific clinical terms, systolic blood pressure (systolic blood pressure) measured at rest is 150 to 160 mmHg or more in adults, and diastolic blood pressure (diastolic blood pressure) is 90 to 95 mmHg or more. The case is treated as high blood pressure.
  • OSCAR is increased compared to the non-hypertensive control model. Therefore, in the prevention or treatment of hypertension as described above, the pharmaceutical composition containing brivudin or a pharmaceutically acceptable salt thereof of the present invention as an active ingredient has oscar inhibitory activity, and thus prevents or treats the hypertension. It can have an effect.
  • the chronic inflammatory lung disease of the present invention may be, but is not limited to, chronic obstructive pulmonary disease (COPD), emphysema, pneumonia, or tuberculosis.
  • COPD chronic obstructive pulmonary disease
  • OSCAR is a receptor for Surfactant Protein D that activates the release of TNF- ⁇ from human CCR2 + inflammatory monocytes.
  • the OSCAR:SP-D interaction may be a potential therapeutic target in chronic inflammatory diseases of the lung and several other diseases associated with tissue accumulation of SP-D, infiltration of inflammatory monocytes, and release of TNF- ⁇ .
  • Serum SP-D levels are associated with lung function or health status in patients with severe chronic obstructive pulmonary disease (COPD) and susceptibility to chronic and infectious lung diseases such as emphysema, pneumococcal lung disease, and tuberculosis.
  • COPD chronic obstructive pulmonary disease
  • the pharmaceutical composition containing brivudin or a pharmaceutically acceptable salt thereof of the present invention as an active ingredient has oscar inhibitory activity, It can have a preventive or therapeutic effect on diseases.
  • Atherosclerosis refers to dysfunction of arterial blood vessels due to lipid accumulation within the walls of arterial blood vessels forming lipid streaks or atherosclerotic plaques.
  • the resulting reduction in arterial vasomotor function due to plaque formation, luminal stenosis and even thrombosis affects the blood supply of tissues and organs supplied by the arteries, resulting in local or global ischemia of tissues and organs.
  • Diabetes is a metabolic disease caused by the abnormal action of insulin and is characterized by hyperglycemia, which increases the concentration of glucose in the blood. Hyperglycemia causes various symptoms and signs and excretes glucose in the urine.
  • Oscar is a novel receptor regulated by oxidized low-density lipoproteins in human endothelial cells.
  • oxidized low-density lipoprotein oxLDL
  • oxLDL oxidized low-density lipoprotein
  • oxLDL oxidized low-density lipoprotein
  • oxLDL oxidized low-density lipoprotein
  • In vivo modified LDL increases OSCAR expression.
  • In vivo modified LDL from diabetic patients increases OSCAR mRNA expression in human endothelial cells.
  • the pharmaceutical composition containing brivudin or a pharmaceutically acceptable salt thereof of the present invention as an active ingredient has oskar-inhibitory activity, and therefore, against the above diseases. It can have preventive or therapeutic effects.
  • the pharmaceutical composition of the present invention can reduce mRNA expression of cartilage degeneration markers.
  • the cartilage degeneration markers include matrix metalloproteinases (MMP)-3, MMP-13, and ADAMTS-5, which function to decompose the extracellular matrix (ECM) of cartilage cells.
  • MMP-3 functions to degrade collagen types II, III, IV, IX and X, proteoglycans, fibronectin, laminin and elastin. also. It also activates other MMPs such as MMP-1, MMP-7, and MMP-9. Therefore, MMP-3 is considered the most important factor in the reorganization of connective tissue.
  • MMP-9 degrades collagen types IV and V and other extracellular matrices, and MMP-12 functions to degrade elastin.
  • MMP-13 is a collagen-degrading enzyme known as collagenase 3 in humans, and is mainly expressed in the skeleton because it is required for the reconstruction of the collagen matrix during the fetal development stage. Very high expression has been observed in pathological situations, such as carcinoma, rheumatoid arthritis, and osteoarthritis.
  • the cartilage degeneration marker may be MMP3 or MMP13, but is not limited thereto.
  • the pharmaceutical composition of the present invention increases the mRNA expression of cartilage regeneration markers.
  • the cartilage regeneration marker may be COL2A1 or SOX9, but is not limited thereto.
  • the SOX9 (SRY (sex determining reiong Y)-box9) is the most important in forming cartilage matrix such as collagen type 2 and aggrecan, which constitute the matrix of cartilage in existing cartilage cells. It is a well-known master transcription factor.
  • the pharmaceutical composition can increase the survival rate of cartilage cells.
  • the inflammatory cytokine IL-1 ⁇ was treated to activate the inflammatory response and chondrocyte death signaling system, and after the chondrocytes were treated with brivudin and further cultured, CCK As a result of confirming cell survival through -8 analysis, it was confirmed that chondrocytes were significantly recovered and survived at concentrations of 5 to 10 ⁇ M of brivudin.
  • the pharmaceutical composition can increase the differentiation of cartilage cells and increase the regeneration of cartilage tissue.
  • the injection of a brivudine substance into the knee cavity of an animal model in which osteoarthritis was induced by DMM surgery was confirmed to have the effect of recovering osteoarthritis that had already occurred and regenerating cartilage.
  • the pharmaceutical composition may have a cartilage regeneration effect even after cartilage degeneration.
  • the effect of cartilage regeneration was confirmed even when intra-articular injection was administered from the second half of the 4th week of the total 8-week period, rather than immediately intra-articularly, in an animal model in which osteoarthritis was induced by DMM surgery. .
  • composition of the present invention may be administered by any method selected from the group consisting of local administration, topical administration, and injection, and the administration by injection may be intra-articular injection. It is not limited to this.
  • Prevention of the present invention refers to all actions that inhibit or delay the occurrence of Oscar-induced disease by administering the pharmaceutical composition of the present invention.
  • Treatment of the present invention refers to all actions that allow treatment of an Oscar-induced disease by administering the pharmaceutical composition of the present invention to a subject in need of treatment of an Oscar-induced disease.
  • the pharmaceutical composition of the present invention can be prepared in the form of a pharmaceutical composition for the treatment of OSCAR-induced diseases, further comprising appropriate carriers (natural or unnatural carriers), excipients or diluents commonly used in the preparation of pharmaceutical compositions.
  • the pharmaceutical composition can be formulated and used in the form of a sterile injectable solution that can be administered according to conventional methods.
  • carriers, excipients, and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, and calcium.
  • examples include silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, collagen, etc.
  • aqueous solutions such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
  • sterilized aqueous solutions non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, suppositories, ointments (for example, dental implants, etc.) may be included.
  • Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable esters such as ethyl oleate.
  • a base for suppositories witepsol, macrogol, tween 61, cacao, laurin, glycerogeratin, etc. can be used.
  • Solid preparations for oral administration include, but are not limited to, tablets, pills, powders, granules, capsules, etc.
  • Such solid preparations may be prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose, lactose, gelatin, etc., in addition to the above active ingredients. Additionally, in addition to simple excipients, lubricants such as magnesium stearate and talc can also be used.
  • it can be prepared by adding various excipients, such as wetting agents, sweeteners, fragrances, and preservatives.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, and preparations.
  • Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
  • injectable esters such as ethyl oleate.
  • Wethepsol, Macrosol, Tween 61, cacao, laurin, glycerogelatin, etc. can be used as a base for suppositories.
  • the content of brivudin included in the pharmaceutical composition of the present invention is not particularly limited, but may be included in an amount of 0.0001 to 50% by weight, more preferably 0.01 to 20% by weight, based on the total weight of the final composition.
  • the pharmaceutical composition of the present invention can be administered in a pharmaceutically effective amount.
  • the pharmaceutically effective amount of the present invention is an amount sufficient to treat or prevent a disease with a reasonable benefit/risk ratio applicable to medical treatment or prevention.
  • the effective dose level is the severity of the disease, the activity of the drug, the patient's age, weight, health, gender, the patient's sensitivity to the drug, the administration time, route of administration and excretion rate of the composition of the present invention used, treatment period, It can be determined according to factors including the composition of the present invention used and the drugs used in combination or concurrently with it, and other factors well known in the medical field.
  • the pharmaceutical composition of the present invention can be administered alone or in combination with a known pharmaceutical composition for treating oskar-induced diseases. It is important to consider all of the above factors and administer the amount that will achieve the maximum effect with the minimum amount without side effects.
  • the appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity, and is skilled in the art. It can be appropriately selected.
  • the frequency of administration of the pharmaceutical composition of the present invention is not particularly limited, but may be administered once a day or divided into multiple doses.
  • Subjects for administration of the present invention include, but are not particularly limited to, humans, monkeys, cows, horses, pigs, sheep, chickens, cats, dogs, mice, rabbits, etc.
  • the present invention provides a method of treating Oscar-induced disease, comprising administering a pharmaceutical composition containing brivudin or a pharmaceutically acceptable salt thereof as an active ingredient to a subject suspected of having Oscar-induced disease.
  • the treatment method of the present invention includes administering a pharmaceutically effective amount of the pharmaceutical composition into a subject suspected of having oskar-induced disease.
  • the subject refers to all mammals including dogs, cows, horses, rabbits, mice, rats, chickens or humans, but the mammals of the present invention are not limited to the above examples.
  • the pharmaceutical composition can be administered parenterally, subcutaneously, intraperitoneally, intrapulmonaryly, intraarticularly and intranasally, and for local treatment, if necessary, by any suitable method including intralesional administration.
  • the preferred dosage of the pharmaceutical composition of the present invention varies depending on the subject's condition and weight, degree of disease, drug form, administration route and period, but can be appropriately selected by a person skilled in the art.
  • brivudin or a pharmaceutically acceptable salt thereof represented by Formula 1 may be used as a method for producing a therapeutic agent for oskar-induced diseases.
  • the present invention provides an oskar inhibitor comprising brivudin or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the Oscar inhibitor of the present invention can inhibit cartilage degeneration markers, promote cartilage regeneration markers, alleviate inflammation, promote differentiation and regeneration of cartilage cells, and alleviate cartilage degeneration.
  • the Oscar inhibitor can prevent or treat Oscar-induced diseases.
  • the Oscar-induced disease may include, but is not limited to, cancer, hypertension, bone metabolic disease, chronic inflammatory lung disease, cardiovascular disease, atherosclerosis, or diabetes.
  • the present invention provides a food composition for preventing or improving Oscar-induced disease, comprising brivudin or a foodologically acceptable salt thereof as an active ingredient.
  • the brivudin of the present invention When using the brivudin of the present invention as a food additive, it can be added as is or used with other foods or ingredients, and can be used appropriately according to conventional methods.
  • the mixing amount of the active ingredient can be appropriately determined depending on the purpose of use.
  • brivudin can be added to foods to which brivudin can be added.
  • foods to which brivudin can be added include meat, sausages, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, and drink preparations.
  • alcoholic beverages and vitamin complexes, etc. can include all foods in the conventional sense, and include foods used as feed for animals.
  • the food composition of the present invention contains various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, and alcohol.
  • it may contain pulp for the production of natural fruit juice, fruit juice drinks, and vegetable drinks.
  • the food can be manufactured in dosage forms such as tablets, granules, powders, capsules, liquid solutions, and pills according to known manufacturing methods.
  • other ingredients, and various common flavoring agents or natural carbohydrates may be included as additional ingredients.
  • the present invention provides a quasi-drug composition for preventing or improving oskar-induced diseases, comprising brivudin or a pharmaceutically acceptable salt thereof as an active ingredient.
  • Quasi-drugs of the present invention refer to products with a milder effect than pharmaceuticals among products used for the purpose of diagnosing, treating, improving, alleviating, treating or preventing diseases in humans or animals.
  • quasi-drugs are used for medicinal purposes. This excludes articles that can be used, and includes fibers or products used to treat or prevent diseases in humans or animals, products that have a minor effect on the human body or are not used directly, and are not instruments or machines, and similar products.
  • the brivudin of the present invention When adding the brivudin of the present invention to a quasi-drug composition for the purpose of preventing or improving oskar-induced diseases, the brivudin can be added as is or used together with other quasi-drug ingredients, and can be used appropriately according to conventional methods.
  • the mixing amount of the active ingredient can be appropriately determined depending on the purpose of use.
  • the present invention provides a feed additive composition for preventing or improving Oscar-induced disease, comprising brivudin or a feedwise acceptable salt thereof as an active ingredient.
  • the feed additive of the present invention is a general term for substances added in trace amounts to animal feed for nutritional or specific purposes.
  • it refers to substances added for the purpose of preventing or improving Oscar-induced diseases.
  • animals are a concept that includes livestock and pets.
  • the feed additive of the present invention may further include binders, emulsifiers, preservatives, etc. added to prevent quality deterioration, and amino acids, vitamins, enzymes, probiotics, flavoring agents, and non-protein nitrogen added to increase utility. It may additionally include compounds, silicate agents, buffers, colorants, extractants, oligosaccharides, etc. In addition, it may additionally include feed mixtures, etc., but is not limited thereto.
  • the present invention relates to a composition for preventing or treating OSCAR-induced diseases containing brivudine as an active ingredient.
  • the composition is an OSCAR inhibitor that reduces OSCAR mRNA expression, relieves inflammation, differentiates chondrocytes, and It can be useful in the treatment of OSCAR-induced diseases, including bone metabolic diseases, by promoting regeneration.
  • Figure 1 is a diagram showing a schematic diagram of drug virtual search technology using artificial intelligence.
  • Figure 2 is a diagram showing a schematic diagram of a binding experiment between OSCAR and a compound.
  • Figure 3 is a diagram showing the results of quantifying the effect of Top 1 to 5, which are OSCAR inhibitory substances, by OSCAR mRNA expression.
  • Figure 4 is a diagram showing the effects of brivudine on controlling OSCAR signaling and inflammatory response signaling in primary chondrocytes.
  • Figure 5 is a diagram showing that brivudin promotes chondrocyte differentiation in bone marrow-derived mesenchymal stem cells.
  • Figure 6 is a diagram showing the inhibitory effect of brivudin on chondrocyte death in an apoptosis activation model.
  • Figure 7 is a diagram showing the effect of relieving osteoarthritis after intra-articular injection of brivudin into the knee of a mouse suffering from osteoarthritis.
  • OSCAR osteoclast-associated Ig-like receptor
  • sBEAR Bioactive compounds Enrichment by Assay Repositioning
  • Brivudine was purchased and used as Cat# B9647 from Sigma-Aldrich, St Louis, MO, USA.
  • Medial meniscus resection surgery is a representative surgical technique that can simulate the symptoms of human osteoarthritis.
  • the medial meniscus is excised by incising the medial part of the knee of C57BL/6J (WT) male mice aged approximately 10 to 12 weeks. After that, DMM surgery to cause cartilage wear was performed again for 8 to 10 weeks.
  • the C57BL/6J male mice were purchased from Japan SLC, Inc. (Hamamatsu, Japan).
  • Adenovirus has low immunogenicity and is very efficient at introducing genes into cells and tissues, so it is widely used as a tool for gene introduction.
  • Adenovirus Ad-Control (1060) and Ad-OSCAR (ADV-267721) were purchased from Vector Biolabs (Malvern, PA, USA). Intra-articular injection of an adenovirus with a gene expected to cause or progress osteoarthritis is a commonly used method of inducing osteoarthritis in mice.
  • Adenovirus (1 x 109 PFU in a total volume of 10 ⁇ l) was injected into the knee joints of mice once a week for 3 weeks. Mice were sacrificed 4 or 9 weeks after the first injection of adenovirus.
  • the present inventors induced osteoarthritis by intraarticular injection of adeno-OSCAR.
  • mice Two cartilage degeneration-inducing animal models of Examples 3-1 and 3-2 were used. Mice were housed in isolation rooms, no more than five per cage, at 24 to 26°C and humidity ranging from 30 to 60% on a 12-hour light/dark cycle. For each experiment, age- and gender-matched mice were used and randomly assigned to each experimental group. All animal experiments were approved by the Ewha Mans University Animal Research Institute Animal Care Committee (IACUC Protocol No: IACUC 21-076) and followed the National Research Council guidelines.
  • mice were fixed in 10% formaldehyde for >24 h at 4°C and dehydrated in 0.5 Methylenediaminetetraacetic acid (EDTA) in PBS (pH 7.4) for 2 weeks. After being limed, it was embedded in paraffin. Next, the paraffin block was cut into 5 ⁇ m sections and incubated with hematoxylin and eosin, 0.1% Safranin-O (s8884, Sigma-Aldrich, St Louis, MO, USA) and 0.05% Fastgreen FCF (f7258, Sigma-Aldrich). Aldrich, St Louis, MO, USA).
  • EDTA Methylenediaminetetraacetic acid
  • Articular cartilage destruction was scored using the standard OA (osteoarthritis) grading OARSI scale (0-6), and sclerosis and articular cartilage destruction were identified using Safranin-O staining and OsteoMeasureXP (OsteoMetrics, Inc., Atlanta, GA, USA), Image-pro plus (v4.5, Media Cybernetics, Inc., Rockville, USA), Adobe photoshop (v9.0, San Jose, CA, USA) and Olympus DP72 charge-coupled device camera ( v2.1, Olympus Corporation, Tokyo, Japan).
  • Subchondral osteosclerosis was determined by measuring the thickness of the subchondral bone plate (SBP). Knee joint sections were incubated overnight at 4°C with primary anti-OSCAR antibody (Cat# SC34235, Santa Cruz Biotechnology, Inc., Dallas, TX, USA and Biorbyt, LLC, St Louis, USA, 1:200 dilution). .
  • SBP subchondral bone plate
  • DAB 3,3'-diaminobenzidine peroxidase
  • MMP3 (Cat# Ab53015, Abcam, Cambridge, MA, USA, 1:50 dilution), MMP13 (Cat# Ab51072, Abcam, 1:25 dilution), Aggrecan (Cat# Ab1031, Abcam 1:100 dilution), COL2A1 (Cat # MAB8887, Sigma-Aldrich, St Louis, MO, USA, 1:50 dilution), ADAMTS5 (Cat# GTX100332, Genetex, Irvine, CA, USA, 1:200 dilution), SOX9 (Cat# ab185230, Abcam 1:50) dilution), TGF ⁇ (Cat# 3711s, Cell Signaling Technology, 1:25), p-smad2 (Cat# ab188334, Abcam 1:50 dilution), and p-smad3 (Cat# ab52903, Abcam 1:25 dilution) Additional immunostaining was performed using .
  • Articular cartilage cell death was determined using the TUNEL assay and a kit from Millipore (Apoptosis Detection kit, Lot #2397039, Temecula, CA, USA). The specimen was visualized using a fluorescence microscope, and the number of apoptotic articular chondrocytes was counted compared to the total number of cells.
  • cDNA complementary DNA
  • Caspase-3 and caspase-8 activities were determined using the caspase colorimetric assay kit (Biovision Research Products, Milpitas, CA, USA). Articular chondrocyte lysates were incubated with substrates for caspase-3 (DEVD-pNA) or caspase-8 (IETD-pNA) for 2 hours at 37°C. The activity of each caspase was determined by measuring absorbance at 405 nm.
  • OSCAR in order to identify the inhibitory effect and point of action of OSCAR within chondrocytes for the active substance brivudine (EK2), which is a competitive inhibitor that inhibits the binding of OSCAR receptors to collagen, OSCAR was conducted through adeno-associated virus in articular chondrocytes in advance. Overexpression experiments were performed.
  • EK2 active substance brivudine
  • chondrocytes were prepared by isolating cells from the femoral limb and tibial disc of ICR mice about 4 to 5 days old. Thereafter, cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 100 ⁇ g/ml streptomycin, treated with hyaluronic acid, and inoculated with adeno-attached OSCAR virus. Through infection experiments, OSCAR was overexpressed in articular chondrocytes.
  • FBS fetal bovine serum
  • penicillin 100 units/ml
  • streptomycin 100 ⁇ g/ml streptomycin
  • brivudin is an effective OSCAR inhibitory substance and has an excellent effect on OSCAR inhibition.
  • the OSCAR signaling system was activated by culturing primary chondrocytes on a culture dish pre-coated with OSCAR-binding Collagen (OSC). Afterwards, brivudine, that is, an EK2 substance, was treated to study the intracellular point of action as an OSCAR inhibitor in chondrocytes.
  • OSC OSC-binding Collagen
  • Bribudine inhibits cartilage degeneration markers (catabolic markers) in an inflammatory activity model.
  • chondrocytes extracted from mouse joints were treated with 10 ng/ml of the inflammatory cytokine IL-1 ⁇ (interleukin-1 ⁇ ) to activate the inflammatory response signaling system, and then treated with brivudin.
  • cytokine IL-1 ⁇ interleukin-1 ⁇
  • cartilage degeneration markers catabolic markers
  • MMP3 and MMP13 were activated due to inflammation was treated with brivudine and changes in mRNA expression of cartilage degeneration markers were measured.
  • Bribudine promotes cartilage regeneration markers (anabolic markers) in an inflammatory activity model.
  • cartilage regeneration markers When inflammation is activated, the expression of cartilage regeneration markers is suppressed, and brivudin was confirmed to significantly increase the expression of these markers. This suggests that the regulation of SOX9, a transcription factor that plays a key role in cartilage formation and development, is achieved through brivudin.
  • BMMSC bone marrow mesenchymal stem cells
  • the mesenchymal stem cells differentiate into chondrocytes among downstream chondrocytes, osteoblasts, and adipocytes ( Figure 5a).
  • Ad-OSCAR Ad-OSCAR
  • brivudin has an effect in controlling cartilage differentiation from stem cells and, in particular, has an effect in promoting differentiation into chondrocytes.
  • CCK8 assay was performed to determine whether the brivudin substance affects the survival (cell viability) of chondrocytes.
  • OSC OSCAR-binding collagen
  • brivudin that is, EK2
  • EK2 effective concentration of brivudin
  • OA osteoarthritis
  • OARSI grade which is an indicator for quantifying the degree of cartilage degeneration
  • degree of osteophyte formation which is one of the methods for determining OA
  • SBP subchondral bone plate
  • the EK2 substance of the present invention is not injected immediately after intra-articular injection (IA injection) after DMM surgery in mice to induce osteoarthritis (OA) in an in vivo experiment, but is administered within a total of 8 weeks of experiment. In the second half, starting from the 4th week, intra-articular injections were administered.
  • composition containing brivudin as an active ingredient of the present invention regulates the OSCAR signaling system, and specifically, the composition reduces OSCAR mRNA expression, alleviates inflammation, and promotes differentiation and regeneration of chondrocytes to treat bone metabolic diseases. It may be useful in treating OSCAR-induced diseases.

Abstract

The present invention relates to a composition for preventing or treating OSCAR-induced diseases, containing brivudine as an active ingredient, and a method for treating OSCAR-induced diseases, comprising the step of administering the composition to a subject with an OSCAR-induced disease. The composition is an OSCAR inhibitor that reduces OSCAR mRNA expression, has the effect of relieving inflammation and promoting differentiation and regeneration of chondrocytes, and thus can be useful in the treatment of OSCAR-induced diseases, including bone metabolic diseases.

Description

브리부딘을 유효성분으로 포함하는 오스카 유도 질환의 예방 또는 치료용 조성물Composition for preventing or treating oskar-induced disease containing brivudin as an active ingredient
본 발명은 브리부딘 (brivudine)을 유효성분으로 포함하는 오스카 (osteoclast-associated Ig-like receptor; OSCAR) 유도 질환의 예방 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing or treating osteoclast-associated Ig-like receptor (OSCAR)-induced diseases containing brivudine as an active ingredient.
오스카 (osteoclast-associated Ig-like receptor; OSCAR)는 백혈구 수용체 복합체에 속하는 2개의 면역글로불린 도메인을 가지는 세포 표면 수용체이다. 오스카는 파골세포 특이적 발현을 통해 파골세포의 분화를 조절한다. 이러한 파골세포의 분화는 파골세포와 조골세포의 상호작용을 통해서 조절된다. 이 과정 중에 조골세포는 세포 외부에 콜라겐을 분비하고, 분비된 콜라겐이 오스카의 리간드로 기능한다. OSCAR (osteoclast-associated Ig-like receptor; OSCAR) is a cell surface receptor with two immunoglobulin domains that belongs to the leukocyte receptor complex. Oscar regulates osteoclast differentiation through osteoclast-specific expression. This differentiation of osteoclasts is regulated through the interaction between osteoclasts and osteoblasts. During this process, osteoblasts secrete collagen outside the cells, and the secreted collagen functions as a ligand for Oscar.
따라서, 콜라겐과 오스카의 상호 결합을 저해하는 활성을 가지는 물질은 오스카의 활성을 억제할 수 있다. 이러한 물질은 콜라겐-오스카 결합에 의해 유도되는 질환의 억제물질로서 활용될 수 있다.Therefore, substances that have the activity of inhibiting the mutual binding of collagen and Oscar can inhibit the activity of Oscar. These substances can be used as inhibitors of diseases induced by collagen-Oscar binding.
오스카 (OSCAR) 유도 질환으로는, 방광암, 유방암, 담관암종, 결장선암종, 식도암, 두경부암, 신장유도세포암, 직장선암종, 위선암종 및 갑상선암종 등을 포함하는 각종 암, 고혈압, 치주질환, 골대사성질환, 류마티스 관절염, 만성 폐쇄성 폐질환, 폐기종, 폐렴, 결핵, 심혈관질환, 죽상동맥경화증, 당뇨병 등이 알려져 있다.OSCAR-induced diseases include various cancers including bladder cancer, breast cancer, cholangiocarcinoma, colon adenocarcinoma, esophageal cancer, head and neck cancer, renal induced cell carcinoma, rectal adenocarcinoma, gastric adenocarcinoma, and thyroid carcinoma, hypertension, periodontal disease, and bone cancer. Metabolic diseases, rheumatoid arthritis, chronic obstructive pulmonary disease, emphysema, pneumonia, tuberculosis, cardiovascular diseases, atherosclerosis, diabetes, etc. are known.
상기 질환에서 OSCAR가 높게 발현되며, OSCAR 수치는 질병의 중증도와 관련이 있음을 나타낸다.OSCAR is highly expressed in the above diseases, and OSCAR levels are associated with the severity of the disease.
한편, 브리부딘 (brivudine)은 대상포진의 치료에 사용되는 것으로 알려진 항바이러스 치료제로 유용하게 사용되며, 표적 바이러스의 복제를 억제시킴으로써 작용한다. 브리부딘은 화학식 1의 구조식을 가지며, 이의 화합물 명칭은 (E)-5-(2-브로모비닐)-2'-데옥시유리딘이다.Meanwhile, brivudine is a useful antiviral treatment known to be used in the treatment of shingles, and acts by inhibiting the replication of the target virus. Bribudin has the structural formula of Formula 1, and its compound name is (E)-5-(2-bromovinyl)-2'-deoxyuridine.
브리부딘은 뉴클레오시드 티미딘 (nucleoside thymidine)의 유사체이고, 활성 화합물은 브리부딘 5'-트리포스페이트이며, 이는 바이러스성 티미딘 키나아제에 의한 인산화에 의해 형성된다. 브리부딘은 장에서 빠르게 흡수되어 간에서 첫번째 신진대사를 거치며, 효소 티미딘 포스포릴라아제는 당 성분을 빠르게 분해하여 30%의 생체 이용률을 유도한다.Bribudin is an analogue of the nucleoside thymidine, and the active compound is brivudin 5'-triphosphate, which is formed by phosphorylation by viral thymidine kinase. Bribudin is quickly absorbed from the intestines and undergoes first metabolism in the liver, and the enzyme thymidine phosphorylase quickly decomposes the sugar component, leading to a bioavailability of 30%.
본 발명자들은 화합물 활성 데이터 기반 약물 정보 탐색 방법인 인공지능 내지 빅데이터 분석에 기반하여, 오스카를 저해하거나 결합하는 화합물을 예의 연구한 결과, 브리부딘 (brivudine)이 오스카 신호전달을 제어하고, OSCAR mRNA 발현을 감소시키는 OSCAR 저해제로서 염증 완화, 연골세포의 분화 및 재생 촉진을 통해 골 대사성 질환을 포함하는 OSCAR 유도 질환 치료 효과를 확인함으로써 본 발명을 완성하였다.The present inventors studied compounds that inhibit or bind to Oscar based on artificial intelligence or big data analysis, which are drug information search methods based on compound activity data. As a result, brivudine controls Oscar signaling and shows that OSCAR mRNA The present invention was completed by confirming the treatment effect of OSCAR-induced diseases, including bone metabolic diseases, by alleviating inflammation and promoting differentiation and regeneration of chondrocytes as an OSCAR inhibitor that reduces expression.
본 발명의 목적은 브리부딘 (brivudine) 또는 이의 약제학적으로 허용가능한 염을 유효성분으로 포함하는, 오스카 (osteoclast-associated Ig-like receptor; OSCAR) 유도 질환의 예방 또는 치료용 약학적 조성물을 제공하는 것이다.The object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of osteoclast-associated Ig-like receptor (OSCAR)-induced diseases, comprising brivudine or a pharmaceutically acceptable salt thereof as an active ingredient. will be.
본 발명의 다른 목적은 상기 약학적 조성물을 오스카 (osteoclast-associated Ig-like receptor; OSCAR) 유도 질환이 의심되는 대상체에 투여하는 단계를 포함하는 오스카 유도 질환의 치료 방법을 제공하는 것이다.Another object of the present invention is to provide a method of treating OSCAR-induced disease, comprising administering the pharmaceutical composition to a subject suspected of having OSCAR (osteoclast-associated Ig-like receptor; OSCAR)-induced disease.
본 발명의 또 다른 목적은 오스카 (osteoclast-associated Ig-like receptor; OSCAR) 유도 질환의 예방, 치료를 위한 브리부딘 (brivudine) 또는 이의 약제학적으로 허용가능한 염의 용도를 제공하는 것이다.Another object of the present invention is to provide a use of brivudine or a pharmaceutically acceptable salt thereof for the prevention and treatment of osteoclast-associated Ig-like receptor (OSCAR)-induced diseases.
본 발명의 또 다른 목적은 오스카 유도 질환의 치료제 제조를 위한 브리부딘 (brivudine) 또는 이의 약제학적으로 허용가능한 염의 용도를 제공하는 것이다.Another object of the present invention is to provide the use of brivudine or a pharmaceutically acceptable salt thereof for manufacturing a therapeutic agent for oskar-induced diseases.
본 발명의 또 다른 목적은 브리부딘 (brivudine) 또는 이의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 오스카 (osteoclast-associated Ig-like receptor; OSCAR) 저해제를 제공하는 것이다.Another object of the present invention is to provide an osteoclast-associated Ig-like receptor (OSCAR) inhibitor containing brivudine or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명의 또 다른 목적은 브리부딘 (brivudine) 또는 이의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 오스카 (osteoclast-associated Ig-like receptor; OSCAR) 저해 방법을 제공하는 것이다.Another object of the present invention is to provide a method for inhibiting osteoclast-associated Ig-like receptor (OSCAR) comprising brivudine or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명의 또 다른 목적은 브리부딘 (brivudine) 또는 이의 식품학적으로 허용가능한 염을 유효성분으로 포함하는, 오스카 (osteoclast-associated Ig-like receptor; OSCAR) 유도 질환의 예방 또는 개선용 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a food composition for preventing or improving osteoclast-associated Ig-like receptor (OSCAR)-induced diseases, comprising brivudine or a food-acceptable salt thereof as an active ingredient. It is done.
본 발명의 또 다른 목적은 브리부딘 (brivudine) 또는 이의 약제학적으로 허용가능한 염을 유효성분으로 포함하는, 오스카 (osteoclast-associated Ig-like receptor; OSCAR) 유도 질환의 예방 또는 개선용 의약외품 조성물을 제공하는 것이다.Another object of the present invention is to provide a quasi-drug composition for preventing or improving osteoclast-associated Ig-like receptor (OSCAR)-induced diseases, comprising brivudine or a pharmaceutically acceptable salt thereof as an active ingredient. It is done.
본 발명의 또 다른 목적은 브리부딘 (brivudine) 또는 이의 사료학적으로 허용가능한 염을 유효성분으로 포함하는, 오스카 (osteoclast-associated Ig-like receptor; OSCAR) 유도 질환의 예방 또는 개선용 사료 첨가제 조성물을 제공하는 것이다.Another object of the present invention is to provide a feed additive composition for preventing or improving osteoclast-associated Ig-like receptor (OSCAR)-induced diseases, which contains brivudine or a feedwise acceptable salt thereof as an active ingredient. It is provided.
본 발명의 이점 및 특징, 그리고 그것들을 달성하는 방법은 첨부되는 도면과 함께 상세하게 후술되어 있는 실시예들을 참조하면 명확해질 것이다. 그러나, 본 발명은 이하에서 개시되는 실시예들에 제한되는 것이 아니라 서로 다른 다양한 형태로 구현될 수 있으며, 단지 본 실시예들은 본 발명의 개시가 완전하도록 하고, 본 발명이 속하는 기술 분야의 통상의 기술자에게 본 발명의 범주를 완전하게 알려주기 위해 제공되는 것이며, 본 발명은 청구항의 범주에 의해 정의될 뿐이다. The advantages and features of the present invention and methods for achieving them will become clear by referring to the embodiments described in detail below along with the accompanying drawings. However, the present invention is not limited to the embodiments disclosed below and may be implemented in various different forms. The present embodiments are merely provided to ensure that the disclosure of the present invention is complete and to provide a general understanding of the technical field to which the present invention pertains. It is provided to fully inform the skilled person of the scope of the present invention, and the present invention is only defined by the scope of the claims.
본 명세서에서 사용된 용어는 실시예들을 설명하기 위한 것이며 본 발명을 제한하고자 하는 것은 아니다. 본 명세서에서, 단수형은 문구에서 특별히 언급하지 않는 한 복수형도 포함한다. 명세서에서 사용되는 "포함한다 (comprises)" 및/또는 "포함하는 (comprising)"은 언급된 구성요소 외에 하나 이상의 다른 구성요소의 존재 또는 추가를 배제하지 않는다. 명세서 전체에 걸쳐 동일한 도면 부호는 동일한 구성 요소를 지칭하며, "및/또는"은 언급된 구성요소들의 각각 및 하나 이상의 모든 조합을 포함한다. 비록 "제1", "제2" 등이 다양한 구성요소들을 서술하기 위해서 사용되나, 이들 구성요소들은 이들 용어에 의해 제한되지 않음은 물론이다. 이들 용어들은 단지 하나의 구성요소를 다른 구성요소와 구별하기 위하여 사용하는 것이다. 따라서, 이하에서 언급되는 제1 구성요소는 본 발명의 기술적 사상 내에서 제2 구성요소일 수도 있음은 물론이다.The terminology used herein is for describing embodiments and is not intended to limit the invention. As used herein, singular forms also include plural forms, unless specifically stated otherwise in the context. As used in the specification, “comprises” and/or “comprising” does not exclude the presence or addition of one or more other elements in addition to the mentioned elements. Like reference numerals refer to like elements throughout the specification, and “and/or” includes each and every combination of one or more of the referenced elements. Although “first”, “second”, etc. are used to describe various components, these components are of course not limited by these terms. These terms are merely used to distinguish one component from another. Therefore, it goes without saying that the first component mentioned below may also be a second component within the technical spirit of the present invention.
다른 정의가 없다면, 본 명세서에서 사용되는 모든 용어(기술 및 과학적 용어를 포함)는 본 발명이 속하는 기술분야의 통상의 기술자에게 공통적으로 이해될 수 있는 의미로 사용될 수 있을 것이다. 또한, 일반적으로 사용되는 사전에 정의되어 있는 용어들은 명백하게 특별히 정의되어 있지 않는 한 이상적으로 또는 과도하게 해석되지 않는다.Unless otherwise defined, all terms (including technical and scientific terms) used in this specification may be used with meanings commonly understood by those skilled in the art to which the present invention pertains. Additionally, terms defined in commonly used dictionaries are not to be interpreted ideally or excessively unless clearly specifically defined.
본 발명은 하기 화학식 1로 표시되는 브리부딘 (brivudine) 또는 이의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 오스카 (osteoclast-associated Ig-like receptor; OSCAR) 유도 질환의 예방 또는 치료용 약학적 조성물을 제공한다.The present invention provides a pharmaceutical composition for the prevention or treatment of osteoclast-associated Ig-like receptor (OSCAR)-induced diseases comprising brivudine or a pharmaceutically acceptable salt thereof represented by the following formula (1) as an active ingredient. provides.
[화학식 1][Formula 1]
Figure PCTKR2023015909-appb-img-000001
Figure PCTKR2023015909-appb-img-000001
본 발명은 오스카 유도 질환의 치료에 사용하기 위한 상기 화학식 1로 표시되는 브리부딘 또는 이의 약제학적으로 허용가능한 염을 제공한다. The present invention provides brivudin or a pharmaceutically acceptable salt thereof represented by Formula 1 for use in the treatment of oskar-induced diseases.
본 발명은 오스카 유도 질환의 치료제 제조를 위한 상기 화학식 1로 표시되는 브리부딘 또는 이의 약제학적으로 허용가능한 염의 용도를 제공한다.The present invention provides the use of brivudin or a pharmaceutically acceptable salt thereof represented by Formula 1 for manufacturing a therapeutic agent for oskar-induced diseases.
본 발명의 브리부딘의 화합물 명칭은 (E)-5-(2-브로모비닐)-2'-데옥시유리딘으로도 지칭된다. 상기 브리부딘 (brivudine)은 대상포진의 치료에 사용되는 것으로 알려진 항바이러스 치료제로 유용하게 사용되며, 표적 바이러스의 복제를 억제시킴으로써 작용한다. 브리부딘은 상기 화학식 1의 구조식을 가진다.The compound name of brivudine of the present invention is also referred to as (E)-5-(2-bromovinyl)-2'-deoxyuridine. The brivudine is useful as an antiviral treatment known to be used in the treatment of shingles, and acts by inhibiting replication of the target virus. Bribudin has the structural formula of Chemical Formula 1 above.
브리부딘은 뉴클레오시드 티미딘 (nucleoside thymidine)의 유사체이고, 활성 화합물은 브리부딘 5'-트리포스페이트이며, 이는 바이러스성 티미딘 키나아제에 의한 인산화에 의해 형성된다. 브리부딘은 장에서 빠르게 흡수되어 간에서 첫번째 신진대사를 거치며, 효소 티미딘 포스포릴라아제는 당 성분을 빠르게 분해하여 30%의 생체 이용률을 유도한다.Bribudin is an analogue of the nucleoside thymidine, and the active compound is brivudin 5'-triphosphate, which is formed by phosphorylation by viral thymidine kinase. Bribudin is quickly absorbed from the intestines and undergoes first metabolism in the liver, and the enzyme thymidine phosphorylase quickly decomposes the sugar component, leading to a bioavailability of 30%.
본 발명의 약제학적으로 허용가능한 염으로는 유리산 (free acid)에 의해 형성된 산부가염이 유용하다. 산부가염은 통상의 방법, 예를 들면 화합물을 과량의 산 수용액에 용해시키고, 이 염을 메탄올, 에탄올, 아세톤 또는 아세토니트릴과 같은 수혼화성 유기 용매를 사용하여 침전시켜서 제조한다. 동일한 몰량의 화합물 및 물 중의 산 또는 알코올(예, 글리콜 모노메틸에테르)을 가열하고 이어서 상기 혼합물을 증발시켜서 건조시키거나, 또는 석출된 염을 흡인 여과시킬 수 있다.As a pharmaceutically acceptable salt of the present invention, an acid addition salt formed by a free acid is useful. Acid addition salts are prepared by conventional methods, for example, by dissolving the compound in an excess of aqueous acid and precipitating the salt using a water-miscible organic solvent such as methanol, ethanol, acetone, or acetonitrile. Equimolar amounts of the compound and an acid or alcohol (e.g., glycol monomethyl ether) in water can be heated and the mixture then evaporated to dryness, or the precipitated salt can be filtered off with suction.
이 때, 유리산으로는 유기산과 무기산을 사용할 수 있으며, 무기산으로는 염산, 인산, 황산, 질산, 주석산 등을 사용할 수 있고 유기산으로는 메탄술폰산, p-톨루엔술폰산, 아세트산, 트리플루오로아 세트산, 시트르산, 말레인산(maleic acid), 숙신산, 옥살산, 벤조산, 타르타르산, 푸마르산, 만데르산, 프로피온산(propionic acid), 구연산(citric acid), 젖산(lactic acid), 글리콜산(glycollic acid), 글루콘산(gluconic acid), 갈락투론산, 글루탐산, 글루타르산(glutaric acid), 글루쿠론산(glucuronic acid), 아스파르트산, 아스코르빈산, 카본산, 바닐릭산 및 히드로 아이오딕산 등을 사용할 수 있다.At this time, organic acids and inorganic acids can be used as free acids. Hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, tartaric acid, etc. can be used as inorganic acids, and methanesulfonic acid, p-toluenesulfonic acid, acetic acid, and trifluoroacetic acid can be used as organic acids. , citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid. (gluconic acid), galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid, and hydroiodic acid can be used.
또한, 염기를 사용하여 약학적으로 허용 가능한 금속염을 만들 수 있다. 알칼리 금속 또는 알칼리토 금속염은, 예를 들면 화합물을 과량의 알칼리 금속 수산화물 또는 알칼리토 금속 수산화물 용액 중에 용해하고, 비 용해 화합물염을 여과한 후 여액을 증발, 건조시켜 얻는다. 이때, 금속염으로서는 특히 나트륨, 칼륨 또는 칼슘염을 제조하는 것이 제약상 적합하며, 또한 이에 대응하는 은염은 알칼리 금속 또는 알칼리토 금속염을 적당한 은염(예, 질산은)과 반응시켜 얻는다.Additionally, a pharmaceutically acceptable metal salt can be prepared using a base. The alkali metal or alkaline earth metal salt is obtained, for example, by dissolving the compound in an excess of alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and then evaporating and drying the filtrate. At this time, it is particularly pharmaceutically suitable to prepare sodium, potassium or calcium salts as metal salts, and the corresponding silver salts are obtained by reacting an alkali metal or alkaline earth metal salt with an appropriate silver salt (eg, silver nitrate).
본 발명의 화합물의 약제학적으로 허용가능한 염은, 달리 지시되지 않는 한, 본 발명의 화합물에 존재할 수 있는 산성 또는 염기성기의 염을 포함한다. 예를 들면, 약제학적으로 허용 가능한 염으로는 히드록시기의 나트륨, 칼슘 및 칼륨염이 포함되며, 아미노기의 기타 약학적으로 허용 가능한 염으로는 하이드로브로마이드, 황산염, 수소 황산염, 인산염, 수소 인산염, 이수소 인산염, 아세테이트, 숙시네이트, 시트레이트, 타르트레이트, 락테이트, 만델레이트, 메탄설포 네이트(메실레이트) 및 p-톨루엔설포네이트(토실레이트) 염이 있으며, 당업계에서 알려진 염의 제조 방법이나 제조과정을 통하여 제조될 수 있다.Pharmaceutically acceptable salts of the compounds of the invention, unless otherwise indicated, include salts of acidic or basic groups that may be present in the compounds of the invention. For example, pharmaceutically acceptable salts include sodium, calcium, and potassium salts of hydroxy groups, and other pharmaceutically acceptable salts of amino groups include hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, and dihydrogen. There are phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulfonate (mesylate), and p-toluenesulfonate (tosylate) salts, and methods or processes for producing salts known in the art. It can be manufactured through.
본 발명의 오스카 (osteoclast-associated Ig-like receptor; OSCAR) 유도 질환은 암, 고혈압, 골대사성질환, 만성 염증성 폐질환, 심혈관질환, 죽상동맥경화증 또는 당뇨병일 수 있으나, 이에 제한되지 않는다.The osteoclast-associated Ig-like receptor (OSCAR)-induced disease of the present invention may include, but is not limited to, cancer, hypertension, bone metabolic disease, chronic inflammatory lung disease, cardiovascular disease, atherosclerosis, or diabetes.
본 발명의 골대사성질환은 골다공증, 관절염, 치주질환, 골절 또는 파제트병일 수 있으며, 상기 관절염은 골관절염 또는 류마티스관절염일 수 있으나, 이에 제한되지 않는다.The bone metabolic disease of the present invention may be osteoporosis, arthritis, periodontal disease, fracture, or Paget's disease, and the arthritis may be osteoarthritis or rheumatoid arthritis, but is not limited thereto.
본 발명의 골 대사성 질환은 조골세포 및 파골세포의 불균형으로 인해 유발되는 골 관련 질환을 의미한다. 상기 골 대사성 질환의 예로는 과도한 파골세포의 골 흡수에 의한 골다공증 (osteoprosis), 관절염 (arthritis), 치주질환 (periodontal disease), 골절 또는 파제트병 (Paget disease) 등과 같은 병리학적 골 질환으로 골 파괴를 촉진하는 질환이 포함되나, 이에 제한되지 않는다.Bone metabolic disease of the present invention refers to a bone-related disease caused by an imbalance between osteoblasts and osteoclasts. Examples of the bone metabolic diseases include bone destruction due to pathological bone diseases such as osteoporosis, arthritis, periodontal disease, fractures, or Paget disease caused by excessive bone resorption by osteoclasts. Diseases that promote, but are not limited to, are included.
상기 골다공증은 뼈의 양이 감소하고 질적인 변화로 인해 뼈의 강도가 약해져서 골절이 일어날 가능성이 높은 상태를 의미한다. 뼈는 인체 내 여러 기관들을 보호하고, 칼슘과 같은 체내에 필요한 물질들을 보관하는 저장소로서 기능하며, 뼈 조직에 존재하는 뼈를 분해하는 파골세포 및 뼈를 생성하는 조골세포 간의 균형에 이어 항상성이 유지된다. 골다공증의 경우에는 두 세포 활성이 균형이 깨지게 되면서 파골세포에 의한 지나친 뼈의 파괴가 일어나 발병 및 진행된다.The osteoporosis refers to a condition in which bone strength is weakened due to a decrease in bone quantity and qualitative changes, making fractures more likely to occur. Bone protects various organs in the human body, functions as a storage site for substances necessary for the body, such as calcium, and maintains homeostasis through the balance between osteoclasts that break down bone present in bone tissue and osteoblasts that produce bone. do. In the case of osteoporosis, the activity of two cells becomes unbalanced and excessive bone destruction by osteoclasts occurs, causing the disease to develop and progress.
상기 관절염은 하나 이상의 관절 부위에 염증을 수반하는 관절 질환을 의미한다. 상기 관절염의 일반적인 형태는 관절을 보호하고 있는 연골의 점진적인 손상이나 퇴행성 변화로 인해 관절을 이루는 뼈와 인대에 손상이 일어나서 염증과 통증이 생기는 골관절염 (osteoarthritis)이다. 본 발명의 관절염은 관절 부위에 뼈 손실을 수반하는 질환으로, 그 종류가 특별히 제한되지 않지만, 골관절염 또는 류마티스관절염일 수 있다.The arthritis refers to a joint disease accompanied by inflammation in one or more joint areas. The common form of arthritis is osteoarthritis, in which inflammation and pain occur due to damage to the bones and ligaments forming the joint due to gradual damage or degenerative changes in the cartilage that protects the joint. Arthritis of the present invention is a disease accompanied by bone loss in the joint area, and the type is not particularly limited, but may be osteoarthritis or rheumatoid arthritis.
본 발명의 골관절염은 퇴행성관절염이라고도 불리우며, 연골의 손상 혹은 퇴행성 변화로 인해 관절을 이루는 뼈와 연골 및 인대 등에 손상이 일어나고, 염증과 통증이 생기는 만성 질환이다. 골관절염은 손가락, 무릎, 엉덩이, 허리, 목 등 체내 거의 모든 관절에서 발병된다. 골관절염의 주요 증상은 반복적인 통증과 관절의 강직감, 기동력 감소 및 기능상실이다. 임상적 경과는 보통 서서히 진행되며, 어느 정도 병이 진행되면서 관절연골의 소실과 변성에 의해 관절면이 불규칙해지면 통증 정도가 심해지고, 점진적인 운동장애로 인해 일상생활에 큰 지장을 초래하게 되고, 관절의 변형도 야기된다.Osteoarthritis of the present invention, also called degenerative arthritis, is a chronic disease in which damage to the bones, cartilage, and ligaments that form joints occurs due to damage or degenerative changes in cartilage, causing inflammation and pain. Osteoarthritis occurs in almost all joints in the body, including fingers, knees, hips, lower back, and neck. The main symptoms of osteoarthritis are repetitive pain, joint stiffness, decreased mobility, and loss of function. The clinical course usually progresses slowly, and as the disease progresses to a certain extent, the joint surface becomes irregular due to loss and degeneration of the articular cartilage, causing severe pain, and gradual movement disorders, which greatly interfere with daily life. Deformation also occurs.
OSCAR 수용체 하류에서 TRAIL 및 OPG의 조절에 따른 연골세포 사멸이 조절되는데, 충격 및 노화로 인한 콜라겐의 분해가 세포외 기질에서 연골세포 표면의 OSCAR를 활성화하여 연골세포의 세포 사멸을 유도할 수 있다. 즉, 연골퇴행 조절에서 연골세포의 세포막 표면 수용체인 OSCAR가 중요한 역할을 하므로, 이는 OSCAR에 의해 골관절염이 발병할 수 있음을 말한다.Chondrocyte death is regulated downstream of the OSCAR receptor by the regulation of TRAIL and OPG. Collagen degradation due to shock and aging can activate OSCAR on the surface of chondrocyte cells in the extracellular matrix, thereby inducing cell death of chondrocyte cells. In other words, since OSCAR, a cell membrane surface receptor of chondrocytes, plays an important role in controlling cartilage degeneration, this means that osteoarthritis can be caused by OSCAR.
상기 류마티스 관절염의 가용성 OSCAR 수치는 상기 질환의 중증도 및 심혈관 질환 위험도와도 관련이 있다. 단핵구에서 OSCAR-콜라겐 신호전달은 염증 촉진 역할을 하며, 류마티스 관절염의 발병기전에 기여할 수 있다.Soluble OSCAR levels in rheumatoid arthritis are also related to the severity of the disease and the risk of cardiovascular disease. OSCAR-collagen signaling in monocytes plays a pro-inflammatory role and may contribute to the pathogenesis of rheumatoid arthritis.
상기 치주질환은 세균에 의해 야기되는 치아지지 조직의 염증상태를 말하며, 치은염 및 치주염으로 분리할 수 있다. 발병원인은 불량한 구강 위생상태로 인한 구강 세균이 치면 세균막을 형성하는 데 있다. 치면 세균막이란 침에 있는 끈끈한 물질을 접착제로 이용하여 세균이 치아 표면에 달라붙은 후 증식한 세균덩어리를 말한다. 치면 세균막은 그냥 방치해 두면, 염증이 생겨 가끔 잇몸에서 피가 나고, 구취가 나는 경우가 있으며 이러한 증상을 치은염이라고 한다. 치은염이 더 진행되면, 치아와 잇몸 사이의 벌어진 틈이 더 깊어져서 치주낭이 생기고, 여기에 치주질환을 일으키는 세균들이 번식하여 치주염이 발생된다.The periodontal disease refers to an inflammatory condition of the tooth-supporting tissue caused by bacteria, and can be divided into gingivitis and periodontitis. The cause of the disease is oral bacteria forming a bacterial film on the teeth due to poor oral hygiene. Dental biofilm refers to a mass of bacteria that grows after sticking to the tooth surface using the sticky substance in saliva as an adhesive. If the bacterial film on the teeth is left untreated, it can become inflamed, causing gums to bleed and bad breath. These symptoms are called gingivitis. As gingivitis progresses further, the gaps between the teeth and gums become deeper, forming periodontal pockets, and the bacteria that cause periodontal disease multiply here, causing periodontitis.
상기 골절은 뼈나 골단판 또는 관절면의 연속성이 비정상적으로 끊어진 상태로, 뼈의 깨짐을 일컫는다. 골절을 유발하는 원인으로는 교통사고 등의 외상, 산업장애에서 일어나는 안전사고, 골다공증, 골암, 대사이상증 등의 질병으로 인한 뼈의 변화 및 스포츠나 하중으로 인한 반복적인 뼈에 대한 스트레스 등이 있다. 또한, 골절 상태는 골절선에 근거하여, 균열 골절, 그린스틱 (greenstick) 골절, 횡상 골절, 사상 골절, 나선상 골절, 분절 골절, 분쇄골절, 견열 골절, 압박 골절, 함몰 골절 등으로 분류될 수 있다.The fracture refers to a state in which the continuity of the bone, epiphyseal plate, or joint surface is abnormally broken, and refers to the breakage of the bone. Causes of fractures include trauma such as traffic accidents, industrial accidents, bone changes due to diseases such as osteoporosis, bone cancer, and metabolic disorders, and repetitive stress on the bones due to sports or load. In addition, based on the fracture line, fracture conditions can be classified into crack fractures, greenstick fractures, transverse fractures, filiform fractures, spiral fractures, segmental fractures, comminuted fractures, avulsion fractures, compression fractures, depressed fractures, etc.
상기 파제트병은 골 재형성이 과도하게 항진되어 광범위한 부위의 골격계가 침범되는 국소성 골질환을 의미한다. 파제트병의 병리학적인 기전은 뼈를 청소하는 기능을 가진 파골 세포에 의한 골 흡수의 과다한 증가와 이에 따른 보상작용으로 뼈를 만드는 기능을 가진 조골 세포에 의한 새로운 골 형성의 증가가 결합된 것으로 알려 져 있으며, 또한, 골 파제트병에서 새롭게 형성된 뼈는 구조적으로 무질서하고 뼈 변형과 골절에 매우 취약한 상태로 알려져 있다.Paget's disease refers to a localized bone disease in which bone remodeling is excessively promoted and a wide area of the skeletal system is invaded. The pathological mechanism of Paget's disease is known to be a combination of an excessive increase in bone resorption by osteoclasts, which have the function of cleaning bones, and an increase in new bone formation by osteoblasts, which have the function of making bones as a compensation. In addition, the newly formed bone in Paget's disease of bone is known to be structurally disordered and very vulnerable to bone deformation and fracture.
상기와 같은 골 대사성 질환의 예방 또는 치료에 있어서, 본 발명의 브리부딘 또는 이의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 약학적 조성물은 오스카 저해 활성을 가지며, 연골 세포의 분화를 촉진시키고, 연골 퇴행 후에도 연골 재생 활성을 나타내므로, 상기 질환들에 대해 예방 또는 치료 효과를 가져올 수 있다.In the prevention or treatment of bone metabolic diseases as described above, the pharmaceutical composition containing brivudin or a pharmaceutically acceptable salt thereof of the present invention as an active ingredient has oscar inhibitory activity, promotes differentiation of chondrocytes, Since it shows cartilage regeneration activity even after cartilage degeneration, it can have a preventive or therapeutic effect on the above diseases.
본 발명의 암은 방광암, 유방암, 담관암종, 결장선암종, 식도암, 두경부암, 신장유도세포암, 직장선암종, 위선암종 또는 갑상선암종일 수 있으나, 이에 제한되지 않는다. 오스카 (OSCAR)는 상기와 같은 여러 암 유형에서 억제 면역 미세 환경과 관련된 강화된 전이로 악성 종양을 촉진시킬 수 있다. OSCAR가 높은 그룹이 통계적으로 유의하게 전이 상태가 더 높았다. OSCAR의 높은 발현은 억제 면역 미세환경과 함께 고려시 바이오마커 역할을 하는 많은 암종에 대해 안좋은 예후와 크게 연관이 되어 있다.The cancer of the present invention may be bladder cancer, breast cancer, cholangiocarcinoma, colon adenocarcinoma, esophageal cancer, head and neck cancer, renal induced cell carcinoma, rectal adenocarcinoma, gastric adenocarcinoma, or thyroid carcinoma, but is not limited thereto. OSCAR can promote malignancy in several cancer types, with enhanced metastasis associated with a suppressive immune microenvironment. The group with high OSCAR had a statistically significantly higher metastatic status. High expression of OSCAR is significantly associated with poor prognosis for many carcinomas, serving as a biomarker when considered together with a suppressive immune microenvironment.
이에, 상기와 같은 암의 예방 또는 치료에 있어서, 본 발명의 브리부딘 또는 이의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 약학적 조성물은 오스카 저해 활성을 가지므로, 상기 암종들에 대해 예방 또는 치료 효과를 가져올 수 있다.Therefore, in the prevention or treatment of the above cancers, the pharmaceutical composition containing brivudin or a pharmaceutically acceptable salt thereof of the present invention as an active ingredient has oscar inhibitory activity, and thus prevents or treats the above carcinomas. It can have a therapeutic effect.
본 발명의 고혈압은 혈압의 비정상적인 상승 상태를 말하며, 구체적인 임상으로는 안정시에 측정한 최고혈압 (수축기 혈압)이 성인의 경우 150~160 mmHg 이상, 최저혈압 (이완기 혈압)이 90~95 mmHg 이상인 경우를 고혈압으로 취급한다. 상기 고혈압 모델에서는 고혈압이 아닌 대조군 모델보다 오스카 (OSCAR)가 증가된다. 따라서, 상기와 같은 고혈압의 예방 또는 치료에 있어서, 본 발명의 브리부딘 또는 이의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 약학적 조성물은 오스카 저해 활성을 가지므로, 상기 고혈압에 대해 예방 또는 치료 효과를 가져올 수 있다.Hypertension of the present invention refers to an abnormally elevated state of blood pressure, and in specific clinical terms, systolic blood pressure (systolic blood pressure) measured at rest is 150 to 160 mmHg or more in adults, and diastolic blood pressure (diastolic blood pressure) is 90 to 95 mmHg or more. The case is treated as high blood pressure. In the hypertensive model, OSCAR is increased compared to the non-hypertensive control model. Therefore, in the prevention or treatment of hypertension as described above, the pharmaceutical composition containing brivudin or a pharmaceutically acceptable salt thereof of the present invention as an active ingredient has oscar inhibitory activity, and thus prevents or treats the hypertension. It can have an effect.
본 발명의 만성 염증성 폐질환은 만성 폐쇄성 폐질환 (COPD), 폐기종, 폐렴 또는 결핵일 수 있으나, 이에 제한되지 않는다. 오스카 (OSCAR)는 인간 CCR2+ 염증성 단핵구에서 TNF-α의 방출을 활성화하는 Surfactant Protein D에 대한 수용체이다. OSCAR:SP-D 상호작용은 폐의 만성 염증성 질환과 SP-D의 조직 축적, 염증성 단핵구의 침윤 및 TNF-α의 방출과 관련된 여러 질환에서 잠재적 치료 타깃이 될 수 있다. 혈청 SP-D 수치는 중증 만성 폐쇄성 폐질환 (COPD) 환자의 폐 기능 또는 건강 상태와 관련이 있고, 폐기종, 폐렴구균성 폐질환 및 결핵과 같은 만성과 감염성 폐질환에 대한 감수성과 관련이 있다.The chronic inflammatory lung disease of the present invention may be, but is not limited to, chronic obstructive pulmonary disease (COPD), emphysema, pneumonia, or tuberculosis. OSCAR is a receptor for Surfactant Protein D that activates the release of TNF-α from human CCR2 + inflammatory monocytes. The OSCAR:SP-D interaction may be a potential therapeutic target in chronic inflammatory diseases of the lung and several other diseases associated with tissue accumulation of SP-D, infiltration of inflammatory monocytes, and release of TNF-α. Serum SP-D levels are associated with lung function or health status in patients with severe chronic obstructive pulmonary disease (COPD) and susceptibility to chronic and infectious lung diseases such as emphysema, pneumococcal lung disease, and tuberculosis.
따라서, 상기와 같은 만성 염증성 폐질환의 예방 또는 치료에 있어서, 본 발명의 브리부딘 또는 이의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 약학적 조성물은 오스카 저해 활성을 가지므로, 상기 만성 염증성 폐질환에 대해 예방 또는 치료 효과를 가져올 수 있다.Therefore, in the prevention or treatment of chronic inflammatory lung diseases as described above, the pharmaceutical composition containing brivudin or a pharmaceutically acceptable salt thereof of the present invention as an active ingredient has oscar inhibitory activity, It can have a preventive or therapeutic effect on diseases.
상기 죽상동맥경화증은 지질 선조 또는 죽상동맥경화성 플라크를 형성하는 동맥 혈관 벽 내의 지질 축적으로 인한 동맥 혈관의 기능 장애를 의미한다. 결과적으로 플라크 형성으로 인한 동맥 혈관운동 기능 감소, 내강 협착 및 심지어 혈전은 동맥에 의해 공급되는 조직 및 장기의 혈액 공급에 영향을 미침으로써, 조직 및 장기의 국소 또는 전체 허혈을 초래한다.The term atherosclerosis refers to dysfunction of arterial blood vessels due to lipid accumulation within the walls of arterial blood vessels forming lipid streaks or atherosclerotic plaques. The resulting reduction in arterial vasomotor function due to plaque formation, luminal stenosis and even thrombosis affects the blood supply of tissues and organs supplied by the arteries, resulting in local or global ischemia of tissues and organs.
상기 당뇨병은 인슐린의 비정상적인 작용으로 인한 대사성 질환으로, 혈중 포도당의 농도가 높아지는 고혈당을 특징으로 하며, 고혈당으로 인해 여러 증상 및 징후를 일으키고 소변에서 포도당을 배출한다.Diabetes is a metabolic disease caused by the abnormal action of insulin and is characterized by hyperglycemia, which increases the concentration of glucose in the blood. Hyperglycemia causes various symptoms and signs and excretes glucose in the urine.
오스카는 인간 내피 세포에서 산화된 저밀도 지단백질에 의해 조절되는 새로운 수용체이다. 특히, 산화된 저밀도 지단백질 (oxLDL)은 내피 세포의 활성화, 염증, 증식, 단핵구 주화성, 세포자멸사 및 변경된 유전자 발현을 촉진하므로 초기 죽상동맥경화증과 관련이 있다. 생체 내 변형 LDL은 OSCAR 발현을 증가시킨다. 당뇨병 환자의 생체 내 변형 LDL은 인간 내피 세포에서 OSCAR mRNA 발현을 증가시킨다.Oscar is a novel receptor regulated by oxidized low-density lipoproteins in human endothelial cells. In particular, oxidized low-density lipoprotein (oxLDL) is associated with early atherosclerosis as it promotes endothelial cell activation, inflammation, proliferation, monocyte chemotaxis, apoptosis, and altered gene expression. In vivo modified LDL increases OSCAR expression. In vivo modified LDL from diabetic patients increases OSCAR mRNA expression in human endothelial cells.
따라서, 상기와 같은 오스카 유도 질환의 예방 또는 치료에 있어서, 본 발명의 브리부딘 또는 이의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 약학적 조성물은 오스카 저해 활성을 가지므로, 상기 질환들에 대해 예방 또는 치료 효과를 가져올 수 있다.Therefore, in the prevention or treatment of the above-mentioned oskar-induced diseases, the pharmaceutical composition containing brivudin or a pharmaceutically acceptable salt thereof of the present invention as an active ingredient has oskar-inhibitory activity, and therefore, against the above diseases. It can have preventive or therapeutic effects.
본 발명의 약학적 조성물은 연골퇴행마커의 mRNA 발현을 감소시킬 수 있다. 상기 연골퇴행마커는 메탈로프로테나아제(matrix metalloproteinases, MMP)-3, MMP-13 및 ADAMTS-5 등이 있으며, 이들은 연골세포의 세포외기질(extracellular matrix, ECM)을 분해하는 기능을 한다. MMP-3는 콜라겐 타입 II, III, IV, IX 및 X, 프로테오글리칸(proteoglycans), 파이브로넥틴(fibronectin), 라미닌(laminin) 및 엘라스틴(elastin)을 분해하는 기능을 한다. 또한. MMP-1, MMP-7 및 MMP-9과 같은 다른 MMP를 활성화시키기도 한다. 따라서 MMP-3는 연결조직의 재구성에 있어 가장 주요한 인자로 여겨지고 있다. MMP-9은 콜라겐 타입 IV 및 V 과 다른 세포외 기질을 분해하며 MMP-12는 엘라스틴을 분해하는 기능을 한다. MMP-13는 인간에서 콜라게나제(collagenase) 3로 알려진 콜라겐 분해효소로서, 태아의 발달단계에서는 콜라겐 매트릭스의 재구성을 위해 필요하기 때문에 주로 골격에서 많이 발현된다. 병적인 상황에서 매우 고발현되는 것이 관찰되었는데, 암종(carcinoma), 류마티스 관절염 및 골관절염에서 이러한 현상이 일어난다.The pharmaceutical composition of the present invention can reduce mRNA expression of cartilage degeneration markers. The cartilage degeneration markers include matrix metalloproteinases (MMP)-3, MMP-13, and ADAMTS-5, which function to decompose the extracellular matrix (ECM) of cartilage cells. MMP-3 functions to degrade collagen types II, III, IV, IX and X, proteoglycans, fibronectin, laminin and elastin. also. It also activates other MMPs such as MMP-1, MMP-7, and MMP-9. Therefore, MMP-3 is considered the most important factor in the reorganization of connective tissue. MMP-9 degrades collagen types IV and V and other extracellular matrices, and MMP-12 functions to degrade elastin. MMP-13 is a collagen-degrading enzyme known as collagenase 3 in humans, and is mainly expressed in the skeleton because it is required for the reconstruction of the collagen matrix during the fetal development stage. Very high expression has been observed in pathological situations, such as carcinoma, rheumatoid arthritis, and osteoarthritis.
본 발명의 일 실시예에서, 상기 연골퇴행마커로는 MMP3 또는 MMP13일 수 있으나, 이에 제한되지 않는다.In one embodiment of the present invention, the cartilage degeneration marker may be MMP3 or MMP13, but is not limited thereto.
기존 퇴행성관절염은 관절이 퇴행하는 기전에 대한 연구가 주로 진행되어 왔다. 그에 따라 퇴행기전을 유도하는 주요 인자는 잘 알려져 있으며, 기존 치료전략 역시 퇴행유도인자를 억제함으로써 질병의 진행을 늦추는데 초점이 맞춰져 있다. 그러나, 이러한 전략은 연골을 재생하는 근본적인 치료효과를 낼 수 없다.In the case of existing degenerative arthritis, research has mainly been conducted on the mechanisms by which joints degenerate. Accordingly, the main factors that induce degeneration mechanisms are well known, and existing treatment strategies are also focused on slowing the progression of the disease by suppressing degeneration-inducing factors. However, this strategy cannot produce a fundamental therapeutic effect in regenerating cartilage.
이에, 본 발명의 약학적 조성물은 연골재생마커의 mRNA 발현을 증가시킴도 확인하였다. 상기 연골재생마커로는 COL2A1 또는 SOX9일 수 있으나, 이에 제한되지 않는다. 상기 SOX9 (SRY(sex determining reiong Y)-box9)은 기존에 연골 세포에서 연골의 매트릭스를 구성하는 콜라겐 유형 2 (collagen type 2)와 아그리칸 (Aggrecan) 등의 연골기질을 형성하는데 있어 가장 중요하다고 잘 알려진 마스터 전사인자이다.Accordingly, it was confirmed that the pharmaceutical composition of the present invention increases the mRNA expression of cartilage regeneration markers. The cartilage regeneration marker may be COL2A1 or SOX9, but is not limited thereto. The SOX9 (SRY (sex determining reiong Y)-box9) is the most important in forming cartilage matrix such as collagen type 2 and aggrecan, which constitute the matrix of cartilage in existing cartilage cells. It is a well-known master transcription factor.
상기 약학적 조성물은 연골 세포의 생존율을 증가시킬 수 있다. 본 발명의 구체적인 일 실시예에서, 연골 세포를 배양한 후 염증성 사이토카인 IL-1β를 처리하여 염증 반응 및 연골세포 사멸 신호체계를 활성화하였고, 브리부딘을 연골 세포에 처리하고 추가 배양한 후, CCK-8 분석을 통해 세포 생존을 확인한 결과 브리부딘 5 내지 10 μM 농도에서 유의하게 연골 세포가 회복되고 생존함을 확인하였다.The pharmaceutical composition can increase the survival rate of cartilage cells. In a specific embodiment of the present invention, after culturing chondrocytes, the inflammatory cytokine IL-1β was treated to activate the inflammatory response and chondrocyte death signaling system, and after the chondrocytes were treated with brivudin and further cultured, CCK As a result of confirming cell survival through -8 analysis, it was confirmed that chondrocytes were significantly recovered and survived at concentrations of 5 to 10 μM of brivudin.
상기 약학적 조성물은 연골 세포의 분화를 증가시키며, 연골 조직의 재생을 증가시킬 수 있다. 본 발명의 구체적인 일 실시예에서, DMM 수술로 골관절염을 유도한 동물 모델의 무릎강 내에 브리부딘 물질을 주사한 결과, 이미 일어난 골관절염이 회복되고 연골이 재생되는 효과를 확인하였다.The pharmaceutical composition can increase the differentiation of cartilage cells and increase the regeneration of cartilage tissue. In one specific embodiment of the present invention, the injection of a brivudine substance into the knee cavity of an animal model in which osteoarthritis was induced by DMM surgery was confirmed to have the effect of recovering osteoarthritis that had already occurred and regenerating cartilage.
또한, 상기 약학적 조성물은 연골 퇴행 후에도 연골 재생 효과를 가질 수 있다. 본 발명의 구체적인 일 실시예에서, DMM 수술로 골관절염을 유도한 동물 모델에 바로 관절내 주사하지 않고, 총 8주의 기간 중 후반부 4주차부터 관절내 주사하는 경우에도, 연골이 재생되는 효과를 확인하였다.Additionally, the pharmaceutical composition may have a cartilage regeneration effect even after cartilage degeneration. In a specific embodiment of the present invention, the effect of cartilage regeneration was confirmed even when intra-articular injection was administered from the second half of the 4th week of the total 8-week period, rather than immediately intra-articularly, in an animal model in which osteoarthritis was induced by DMM surgery. .
본 발명의 조성물은 국부 투여(local administration), 국소 투여 (topical administration) 및 주사로 구성된 군으로부터 선택된 어느 하나의 방법으로 투여될 수 있으며, 상기 주사에 의한 투여는 관절 내 주사에 의한 것일 수 있으나, 이에 제한되지 않는다.The composition of the present invention may be administered by any method selected from the group consisting of local administration, topical administration, and injection, and the administration by injection may be intra-articular injection. It is not limited to this.
본 발명의 예방은 본 발명의 약학적 조성물의 투여로 오스카 유도 질환의 발생을 저해 또는 지연시키는 모든 행위를 의미한다.Prevention of the present invention refers to all actions that inhibit or delay the occurrence of Oscar-induced disease by administering the pharmaceutical composition of the present invention.
본 발명의 치료는 본 발명의 약학적 조성물을 오스카 유도 질환의 치료가 요구되는 대상체에 투여하여, 오스카 유도 질환의 치료가 수행되도록 하는 모든 행위를 의미한다.Treatment of the present invention refers to all actions that allow treatment of an Oscar-induced disease by administering the pharmaceutical composition of the present invention to a subject in need of treatment of an Oscar-induced disease.
본 발명의 약학적 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체 (자연적 또는 비자연적 담체), 부형제 또는 희석제를 추가로 포함하는 OSCAR 유도 질환의 치료용 약학적 조성물의 형태로 제조될 수 있다. 구체적으로, 상기 약학적 조성물은 통상의 방법에 따라 투여할 수 있는 멸균 주사용액의 형태로 제형화하여 사용될 수 있다.The pharmaceutical composition of the present invention can be prepared in the form of a pharmaceutical composition for the treatment of OSCAR-induced diseases, further comprising appropriate carriers (natural or unnatural carriers), excipients or diluents commonly used in the preparation of pharmaceutical compositions. there is. Specifically, the pharmaceutical composition can be formulated and used in the form of a sterile injectable solution that can be administered according to conventional methods.
본 발명에서, 상기 약학적 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토오스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로픽히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 광물유, 콜라겐 등을 들 수 있다.In the present invention, carriers, excipients, and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, and calcium. Examples include silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, collagen, etc.
제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 특히, 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결 건조 제제, 좌제, 연고제 (예를 들어, 치수이장재 등) 등이 포함될 수 있다. 비수성용제, 현탁제로는 프로필렌글리콜, 폴리에틸렌글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔 (witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.When formulated, it can be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. In particular, sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, suppositories, ointments (for example, dental implants, etc.) may be included. Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable esters such as ethyl oleate. As a base for suppositories, witepsol, macrogol, tween 61, cacao, laurin, glycerogeratin, etc. can be used.
경구투여를 위한 고형 제제로는 정제, 환제, 산제, 과립제, 캡슐제 등을 포함하나, 이에 한정되는 것은 아니다. 이러한 고형 제제는 상기 유효성분 외에 적어도 하나 이상의 부형제, 예를 들면, 전분, 칼슘 카보네이트, 수크로오스, 락토오스, 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구를 위한 액상물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등을 첨가하여 조제될 수 있다.Solid preparations for oral administration include, but are not limited to, tablets, pills, powders, granules, capsules, etc. Such solid preparations may be prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose, lactose, gelatin, etc., in addition to the above active ingredients. Additionally, in addition to simple excipients, lubricants such as magnesium stearate and talc can also be used. In addition to oral liquid and liquid paraffin, it can be prepared by adding various excipients, such as wetting agents, sweeteners, fragrances, and preservatives.
비경구 투여를 위한 제제는 멸균된 수용액, 비수성 용제, 현탁제, 유제, 동결건조 제제 및 과제를 포함한다. 비수성 용제 및 현탁제로는 프로필렌글리콜, 폴리에틸렌글리콜, 올리브 오일과 같은 식물성 오일, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔, 마크로솔, 트윈 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, and preparations. Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As a base for suppositories, Wethepsol, Macrosol, Tween 61, cacao, laurin, glycerogelatin, etc. can be used.
본 발명의 약학적 조성물에 포함된 브리부딘의 함량은 특별히 이에 제한되지 않으나, 최종 조성물 총 중량을 기준으로 0.0001 내지 50 중량%, 보다 바람직하게는 0.01 내지 20 중량%의 함량으로 포함될 수 있다.The content of brivudin included in the pharmaceutical composition of the present invention is not particularly limited, but may be included in an amount of 0.0001 to 50% by weight, more preferably 0.01 to 20% by weight, based on the total weight of the final composition.
본 발명의 약학적 조성물은 약제학적으로 유효한 양으로 투여될 수 있는데, 본 발명의 약제학적으로 유효햔 양은 의학적 치료 또는 예방에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료 또는 예방하기에 충분한 양을 의미하며, 유효 용량 수준은 질환의 중증도, 약물의 활성, 환자의 연령, 체중, 건강, 성별, 환자의 약물에 대한 민감도, 사용된 본 발명의 조성물의 투여 시간, 투여 경로 및 배출 비율 치료기간, 사용된 본 발명의 조성물과 배합 또는 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다.The pharmaceutical composition of the present invention can be administered in a pharmaceutically effective amount. The pharmaceutically effective amount of the present invention is an amount sufficient to treat or prevent a disease with a reasonable benefit/risk ratio applicable to medical treatment or prevention. This means that the effective dose level is the severity of the disease, the activity of the drug, the patient's age, weight, health, gender, the patient's sensitivity to the drug, the administration time, route of administration and excretion rate of the composition of the present invention used, treatment period, It can be determined according to factors including the composition of the present invention used and the drugs used in combination or concurrently with it, and other factors well known in the medical field.
본 발명의 약학적 조성물은 단독으로 투여하거나, 공지된 오스카 유도 질환치료용 약학적 조성물과 병용하여 투여될 수 있다. 상기 요소를 모두 고려하여 부작용 없이 최소한의 양으로 최대의 효과를 얻을 수 있는 양을 투여하는 것이 중요하다.The pharmaceutical composition of the present invention can be administered alone or in combination with a known pharmaceutical composition for treating oskar-induced diseases. It is important to consider all of the above factors and administer the amount that will achieve the maximum effect with the minimum amount without side effects.
본 발명의 약학적 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 따라 다르며, 당업자에 의하여 적절하게 선택될 수 있다.The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity, and is skilled in the art. It can be appropriately selected.
본 발명의 약학적 조성물의 투여빈도는 특별히 이에 제한되지 않으나, 1일 1회 투여하거나 또는 용량을 분할하여 수회 투여할 수 있다.The frequency of administration of the pharmaceutical composition of the present invention is not particularly limited, but may be administered once a day or divided into multiple doses.
본 발명의 투여 대상은 인간, 원숭이, 소, 말, 돼지, 양, 닭, 고양이, 개, 마우스, 토끼 등을 포함하지만, 특별히 이에 제한되지 않는다.Subjects for administration of the present invention include, but are not particularly limited to, humans, monkeys, cows, horses, pigs, sheep, chickens, cats, dogs, mice, rabbits, etc.
또한, 본 발명은 브리부딘 또는 이의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 약학적 조성물을 오스카 유도 질환이 의심되는 대상체에 투여하는 단계를 포함하는 오스카 유도 질환의 치료 방법을 제공한다.Additionally, the present invention provides a method of treating Oscar-induced disease, comprising administering a pharmaceutical composition containing brivudin or a pharmaceutically acceptable salt thereof as an active ingredient to a subject suspected of having Oscar-induced disease.
본 발명의 치료 방법은 상기 약학적 조성물을 약학적 유효량으로 오스카 유도 질환 의심 대상체 내에 투여하는 것을 포함한다. 상기 대상체는 개, 소, 말, 토끼, 마우스, 랫트, 닭 또는 인간을 포함하는 포유류 전체를 의미하나, 상기 예에 의해 본 발명의 포유류가 제한되는 것은 아니다. The treatment method of the present invention includes administering a pharmaceutically effective amount of the pharmaceutical composition into a subject suspected of having oskar-induced disease. The subject refers to all mammals including dogs, cows, horses, rabbits, mice, rats, chickens or humans, but the mammals of the present invention are not limited to the above examples.
상기 약학적 조성물은 비경구, 피하, 복강 내, 폐 내, 관절강 내 및 비강 내로 투여될 수 있고, 국부적 치료를 위해, 필요하다면 병변 내 투여를 포함하는 적합한 방법에 의하여 투여될 수 있다. 본 발명의 상기 약학적 조성물의 바람직한 투여량은 대상체의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다.The pharmaceutical composition can be administered parenterally, subcutaneously, intraperitoneally, intrapulmonaryly, intraarticularly and intranasally, and for local treatment, if necessary, by any suitable method including intralesional administration. The preferred dosage of the pharmaceutical composition of the present invention varies depending on the subject's condition and weight, degree of disease, drug form, administration route and period, but can be appropriately selected by a person skilled in the art.
본 발명의 다른 양태는 오스카 유도 질환 치료제를 제조하기 위한 방법으로 상기 화학식 1로 표시되는 브리부딘 또는 이의 약제학적으로 허용가능한 염을 사용할 수 있다.In another aspect of the present invention, brivudin or a pharmaceutically acceptable salt thereof represented by Formula 1 may be used as a method for producing a therapeutic agent for oskar-induced diseases.
또한, 본 발명은 브리부딘 또는 이의 약제학적으로 허용가능한 염을 유효성분으로 포함하는, 오스카 저해제를 제공한다.Additionally, the present invention provides an oskar inhibitor comprising brivudin or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명의 오스카 저해제는 연골퇴행마커를 저해하고, 연골재생마커를 촉진하며, 염증 완화, 연골세포의 분화 및 재생을 촉진하고, 연골퇴행을 완화시킬 수 있다. 상기 오스카 저해제는 오스카 유도 질환을 예방 또는 치료할 수 있다. 상기 오스카 유도 질환으로는 암, 고혈압, 골대사성질환, 만성 염증성 폐질환, 심혈관질환, 죽상동맥경화증 또는 당뇨병일 수 있으나, 이에 제한되지 않는다.The Oscar inhibitor of the present invention can inhibit cartilage degeneration markers, promote cartilage regeneration markers, alleviate inflammation, promote differentiation and regeneration of cartilage cells, and alleviate cartilage degeneration. The Oscar inhibitor can prevent or treat Oscar-induced diseases. The Oscar-induced disease may include, but is not limited to, cancer, hypertension, bone metabolic disease, chronic inflammatory lung disease, cardiovascular disease, atherosclerosis, or diabetes.
또한, 본 발명은 브리부딘 또는 이의 식품학적으로 허용가능한 염을 유효성분으로 포함하는, 오스카 유도 질환 예방 또는 개선용 식품 조성물을 제공한다.In addition, the present invention provides a food composition for preventing or improving Oscar-induced disease, comprising brivudin or a foodologically acceptable salt thereof as an active ingredient.
본 발명의 브리부딘을 식품 첨가물로 사용할 경우, 그대로 첨가하거나 다른 식품 또는 성분과 함께 사용할 수 있고, 통상적인 방법에 따라 적절하게 사용할 수 있다. 유효 성분의 혼합량은 사용 목적에 따라 적합하게 결정할 수 있다.When using the brivudin of the present invention as a food additive, it can be added as is or used with other foods or ingredients, and can be used appropriately according to conventional methods. The mixing amount of the active ingredient can be appropriately determined depending on the purpose of use.
본 발명의 식품의 종류에는 특별한 제한은 없다. 상기 브리부딘을 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등이 있고, 통상적인 의미에서의 식품을 모두 포함할 수 있으며, 동물을 위한 사료로 이용되는 식품을 포함한다.There is no particular limitation on the type of food of the present invention. Examples of foods to which brivudin can be added include meat, sausages, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, and drink preparations. , alcoholic beverages and vitamin complexes, etc., can include all foods in the conventional sense, and include foods used as feed for animals.
상기 외에 본 발명의 식품 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음 료에 사용되는 탄 산화제 등을 함유할 수 있다. 그밖에 천연 과일쥬스, 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 또한, 상기 식품은 공지의 제조방법에 따라 정제, 과립, 분말, 캅셀, 액상의 용액 및 환 등의 제형으로도 제조될 수 있다. 본 발명의 브리부딘을 유효성분으로 포함하는 것 이외에는 다른 성분에는 특별한 제한이 없으며, 통상의 여러가지 향미제 또는 천연 탄수화물 등을 추가 성분으로 포함할 수 있다.In addition to the above, the food composition of the present invention contains various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, and alcohol. , may contain carbonating agents used in carbonated drinks, etc. In addition, it may contain pulp for the production of natural fruit juice, fruit juice drinks, and vegetable drinks. In addition, the food can be manufactured in dosage forms such as tablets, granules, powders, capsules, liquid solutions, and pills according to known manufacturing methods. Other than including the brivudin of the present invention as an active ingredient, there are no particular restrictions on other ingredients, and various common flavoring agents or natural carbohydrates may be included as additional ingredients.
또한, 본 발명은 브리부딘 또는 이의 약제학적으로 허용가능한 염을 유효성분으로 포함하는, 오스카 유도 질환 예방 또는 개선용 의약외품 조성물을 제공한다.In addition, the present invention provides a quasi-drug composition for preventing or improving oskar-induced diseases, comprising brivudin or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명의 의약외품은 사람이나 동물의 질병을 진단, 치료, 개선, 경감, 처치 또는 예방할 목적으로 사용되는 물품들 중 의약품보다 작용이 경미한 물품들을 의미하는 것으로, 약사법에 따르면 의약외품이란 의약품의 용도로 사용되는 물품을 제외한 것으로, 사람이나 동물의 질병 치료나 예방에 쓰이는 섬유 또는 제품, 인체에 대한 작용이 경미하거나 직접 사용하지 않으며, 기구 또는 기계가 아닌 것과 이와 유사한 것 등이 이에 포함된다.Quasi-drugs of the present invention refer to products with a milder effect than pharmaceuticals among products used for the purpose of diagnosing, treating, improving, alleviating, treating or preventing diseases in humans or animals. According to the Pharmaceutical Affairs Act, quasi-drugs are used for medicinal purposes. This excludes articles that can be used, and includes fibers or products used to treat or prevent diseases in humans or animals, products that have a minor effect on the human body or are not used directly, and are not instruments or machines, and similar products.
본 발명의 브리부딘을 오스카 유도 질환의 예방 또는 개선을 목적으로 의약외품 조성물에 첨가할 경우, 상기 브리부딘을 그대로 첨가하거나 다른 의약외품 성분과 함께 사용할 수 있고, 통상적인 방법에 따라 적절하게 사용할 수 있다. 유효 성분의 혼합량은 사용 목적에 따라 적합하게 결정할 수 있다.When adding the brivudin of the present invention to a quasi-drug composition for the purpose of preventing or improving oskar-induced diseases, the brivudin can be added as is or used together with other quasi-drug ingredients, and can be used appropriately according to conventional methods. The mixing amount of the active ingredient can be appropriately determined depending on the purpose of use.
또한, 본 발명은 브리부딘 또는 이의 사료학적으로 허용가능한 염을 유효성분으로 포함하는 오스카 유도 질환의 예방 또는 개선용 사료 첨가제 조성물을 제공한다.In addition, the present invention provides a feed additive composition for preventing or improving Oscar-induced disease, comprising brivudin or a feedwise acceptable salt thereof as an active ingredient.
본 발명의 사료 첨가제는 영양적 또는 특정 목적을 위하여 동물을 대상으로 하는 사료에 미량으로 첨가되는 물질을 총칭하는 것으로, 본 발명에서는 오스카 유도 질환의 예방 또는 개선을 목적으로 첨가되는 물질을 의미한다. 여기서, 동물이란 가축 및 애완동물을 포함하는 개념이다.The feed additive of the present invention is a general term for substances added in trace amounts to animal feed for nutritional or specific purposes. In the present invention, it refers to substances added for the purpose of preventing or improving Oscar-induced diseases. Here, animals are a concept that includes livestock and pets.
본 발명의 사료 첨가제에는 품질 저하를 방지하기 위해 첨가되는 결착제, 유화제, 보존제 등을 추가로 포함할 수 있고, 효용 증대를 위하여 첨가되는 아미노산제, 비타민제, 효소제, 생균제, 향미제, 비단백태 질소화합물, 규산염제, 완충제, 착색제, 추출제, 올리고당 등을 추가로 포함할 수 있으며, 그 외에도 사료 혼합제 등을 추가로 포함할 수 있으며, 이에 제한되지 않는다.The feed additive of the present invention may further include binders, emulsifiers, preservatives, etc. added to prevent quality deterioration, and amino acids, vitamins, enzymes, probiotics, flavoring agents, and non-protein nitrogen added to increase utility. It may additionally include compounds, silicate agents, buffers, colorants, extractants, oligosaccharides, etc. In addition, it may additionally include feed mixtures, etc., but is not limited thereto.
본 발명은 브리부딘 (brivudine)을 유효성분으로 포함하는 오스카 (OSCAR) 유도 질환의 예방 또는 치료용 조성물에 관한 것으로, 상기 조성물은 OSCAR mRNA 발현을 감소시키는 OSCAR 저해제로서 염증 완화, 연골세포의 분화 및 재생 촉진을 통해 골 대사성 질환을 포함하는 OSCAR 유도 질환 치료에 유용하게 사용될 수 있다.The present invention relates to a composition for preventing or treating OSCAR-induced diseases containing brivudine as an active ingredient. The composition is an OSCAR inhibitor that reduces OSCAR mRNA expression, relieves inflammation, differentiates chondrocytes, and It can be useful in the treatment of OSCAR-induced diseases, including bone metabolic diseases, by promoting regeneration.
도 1은 인공지능을 활용한 약물 가상탐색 기술 모식도를 나타낸 도이다.Figure 1 is a diagram showing a schematic diagram of drug virtual search technology using artificial intelligence.
도 2는 오스카 (OSCAR)와 화합물 간의 결합 실험 모식도를 나타낸 도이다.Figure 2 is a diagram showing a schematic diagram of a binding experiment between OSCAR and a compound.
도 3은 OSCAR 저해 유효물질인 Top 1 내지 5의 효과를 OSCAR mRNA 발현으로 정량한 결과를 나타낸 도이다.Figure 3 is a diagram showing the results of quantifying the effect of Top 1 to 5, which are OSCAR inhibitory substances, by OSCAR mRNA expression.
도 4는 일차 연골세포에서 브리부딘 (brivudine)의 OSCAR 신호전달 제어 및 염증반응 신호전달 조절 효과를 나타낸 도이다.Figure 4 is a diagram showing the effects of brivudine on controlling OSCAR signaling and inflammatory response signaling in primary chondrocytes.
도 5는 골수 유래 중간엽 줄기세포에서 브리부딘의 연골세포 분화를 촉진하는 것을 나타낸 도이다.Figure 5 is a diagram showing that brivudin promotes chondrocyte differentiation in bone marrow-derived mesenchymal stem cells.
도 6은 세포사멸 활성화 모델에서 브리부딘의 연골세포 사멸 억제 효과를 나타낸 도이다.Figure 6 is a diagram showing the inhibitory effect of brivudin on chondrocyte death in an apoptosis activation model.
도 7은 골관절염이 유발된 마우스 무릎에 브리부딘을 관절강 주사한 후 골관절염 완화 효과를 나타낸 도이다.Figure 7 is a diagram showing the effect of relieving osteoarthritis after intra-articular injection of brivudin into the knee of a mouse suffering from osteoarthritis.
이하, 본 발명의 내용을 하기의 실시예 및 실험예를 통해 더욱 상세히 설명하고자 한다. 다만, 본 발명의 권리범위가 하기 실시예 및 실험예에만 한정되는 것은 아니고, 이와 등가의 기술적 사상의 변형까지를 포함한다.Hereinafter, the contents of the present invention will be described in more detail through the following examples and experimental examples. However, the scope of the present invention is not limited to the following examples and experimental examples, and includes modifications of the technical idea equivalent thereto.
실시예 1. 오스카 (OSCAR)-콜라겐 결합 제어 물질 탐색Example 1. Search for OSCAR-collagen binding control substances
오스카 (osteoclast-associated Ig-like receptor; OSCAR)를 저해하거나, 오스카에 결합할 것으로 예상되는 화합물을 찾고자 약물 가상탐색방법 (structurally similar Bioactive compounds Enrichment by Assay Repositioning; sBEAR)을 이용하였다. 상기 sBEAR 알고리즘은 대규모 화합물 활성 데이터 (1억 포인트 이상)를 활용하여, 주어진 타겟의 리간드로부터 유사 활성 패턴을 보이는 새로운 화합물을 예측하는 방법이다 (도 1).To find compounds expected to inhibit or bind to OSCAR (osteoclast-associated Ig-like receptor; OSCAR), a virtual drug discovery method (structurally similar Bioactive compounds Enrichment by Assay Repositioning; sBEAR) was used. The sBEAR algorithm is a method of predicting new compounds showing similar activity patterns from the ligand of a given target by utilizing large-scale compound activity data (more than 100 million points) (Figure 1).
즉, 오스카-콜라겐 결합을 제어할 수 있는 오스카 저해제를 탐색하기 위해 화합물 스크리닝을 수행하였다. 먼저, 오스카 리간드로 특정 서열 (GPO-GPX-GFX)의 3차 나선구조를 포함하는 콜라겐을 플레이트 (plate)에 미리 코팅하였다. 이후, 인간 유래 오스카와 세포 내 도메인 Fc region을 융합한 hOSCAR-Fc를 넣어주면, OSCAR와 콜라겐의 결합은 2차 항체 처리 후 optical density 450 (OD 450 nm)에서 효소면역정량법 (enzyme-linked Immunosorbent assay; ELISA)으로 확인하였다. 즉, 값이 클수록 강한 결합을 의미한다.That is, compound screening was performed to search for an Oscar inhibitor that can control Oscar-collagen binding. First, collagen containing a tertiary helix structure of a specific sequence (GPO-GPX-GFX) was previously coated on a plate with an Oscar ligand. Afterwards, when hOSCAR-Fc, which is a fusion of human-derived OSCAR and the intracellular domain Fc region, is added, the binding between OSCAR and collagen is confirmed by enzyme-linked immunosorbent assay at optical density 450 (OD 450 nm) after secondary antibody treatment. confirmed by ELISA). In other words, the larger the value, the stronger the bond.
이때 hOSCAR-Fc를 OSCAR 저해제 후보와 플레이트 밖에서 사전적으로 결합하게 한 후 플레이트에 넣으면, OSCAR 저해제가 OSCAR와 콜라겐 결합을 경쟁적으로 저해 (competitive inhibition)하면서 hOSCAR-Fc가 콜라겐에 결합하지 못해 씻겨 나가고, OD 450 nm 값도 낮게 측정된다 (도 2).At this time, when hOSCAR-Fc is preliminarily bound to the OSCAR inhibitor candidate outside the plate and then added to the plate, the OSCAR inhibitor competitively inhibits the binding of OSCAR and collagen, and hOSCAR-Fc is unable to bind to collagen and is washed away, resulting in OD The 450 nm value is also measured to be low (Figure 2).
상기 스크리닝을 통해 OSCAR와 콜라겐의 결합을 가장 효과적으로 저해하는 유효물질을 확보하였고, 반복 실험을 통해 OSCAR 저해 효과가 우수한 화합물인 브리부딘 (brivudine)을 특정하였고, 본원에서 이를 EK2 (Ewha-Kaipharm 2)로도 명명하였다.Through the above screening, an active substance that most effectively inhibits the binding of OSCAR and collagen was secured, and through repeated experiments, brivudine, a compound with excellent OSCAR inhibition effect, was identified, and herein, it was identified as EK2 (Ewha-Kaipharm 2). It was also named.
실시예 2. 실험 재료 준비Example 2. Preparation of experimental materials
브리부딘 (brivudine)은 Cat# B9647로, Sigma-Aldrich, St Louis, MO, USA에서 구입하여 사용하였다.Brivudine was purchased and used as Cat# B9647 from Sigma-Aldrich, St Louis, MO, USA.
실시예 3. 연골퇴행 유발 질환 동물모델 제작Example 3. Production of animal model for diseases causing cartilage degeneration
3-1. 내측 반월상 연골판 절제 (destabilization of medial meniscus; DMM)3-1. destabilization of medial meniscus (DMM)
내측 반월상 연골판 절제 수술은 인간의 골관절염 증상을 모사할 수 있는 대표적인 수술 기법으로, 생후 10 내지 12 주령 정도 경과한 C57BL/6J (WT) 수컷 마우스 무릎의 내측 부분을 절개하여 내측 반월상 연골판을 절제한 후, 다시 8 내지 10주 동안 연골 마모를 유발하는 DMM 수술을 수행하였다. 상기 C57BL/6J 수컷 마우스를 Japan SLC, Inc. (Hamamatsu, Japan)로부터 구입하였다.Medial meniscus resection surgery is a representative surgical technique that can simulate the symptoms of human osteoarthritis. The medial meniscus is excised by incising the medial part of the knee of C57BL/6J (WT) male mice aged approximately 10 to 12 weeks. After that, DMM surgery to cause cartilage wear was performed again for 8 to 10 weeks. The C57BL/6J male mice were purchased from Japan SLC, Inc. (Hamamatsu, Japan).
3-2. 아데노 부속 바이러스 관절강 주사 (Intra-articular injection of Adeno-associated virus)3-2. Intra-articular injection of Adeno-associated virus
아데노바이러스는 면역원성이 낮고, 세포와 조직에 대해 유전자 도입 효율이 매우 높아 유전자 도입의 도구로 널리 사용된다. 아데노바이러스 Ad-Control (1060) 및 Ad-OSCAR (ADV-267721)은 Vector Biolabs (Malvern, PA, USA)에서 구입하였다. 골관절염을 유발하거나 진행시킬 것으로 예상되는 유전자의 아데노바이러스를 관절강 내 주사하는 방법은 마우스에서 대표적으로 사용되는 골관절염 유발 방법이다.Adenovirus has low immunogenicity and is very efficient at introducing genes into cells and tissues, so it is widely used as a tool for gene introduction. Adenovirus Ad-Control (1060) and Ad-OSCAR (ADV-267721) were purchased from Vector Biolabs (Malvern, PA, USA). Intra-articular injection of an adenovirus with a gene expected to cause or progress osteoarthritis is a commonly used method of inducing osteoarthritis in mice.
아데노바이러스 (총 부피 10 μl에 1 x 109 PFU)를 마우스의 무릎 관절에 3주 동안 1주일에 1회 주사하였다. 아데노바이러스의 첫번째 주사 후 4주 또는 9주 후에 마우스를 희생시켰다.Adenovirus (1 x 109 PFU in a total volume of 10 μl) was injected into the knee joints of mice once a week for 3 weeks. Mice were sacrificed 4 or 9 weeks after the first injection of adenovirus.
즉, 본 발명자들은 adeno-OSCAR를 관절강 내 주사하여 골관절염을 유발하였다.That is, the present inventors induced osteoarthritis by intraarticular injection of adeno-OSCAR.
상기 실시예 3-1 및 3-2의 2가지 연골 퇴행 유발 동물모델을 이용하였다. 마우스는 12시간 명/암 주기로 30 내지 60 % 범위의 습도와 24 내지 26 ℃에서 케이지당 5개 이하의 차단 시설에 수용되었다. 각 실험에는 연령 및 성별이 일치하는 마우스를 사용하여 각 실험군에 무작위로 할당하였다. 모든 동물 실험은 이화여자대학교 동물연구소 동물관리위원회 (IACUC Protocol No: IACUC 21-076)의 승인을 받았고, 국가연구협의회 가이드라인을 준수하였다.Two cartilage degeneration-inducing animal models of Examples 3-1 and 3-2 were used. Mice were housed in isolation rooms, no more than five per cage, at 24 to 26°C and humidity ranging from 30 to 60% on a 12-hour light/dark cycle. For each experiment, age- and gender-matched mice were used and randomly assigned to each experimental group. All animal experiments were approved by the Ewha Womans University Animal Research Institute Animal Care Committee (IACUC Protocol No: IACUC 21-076) and followed the National Research Council guidelines.
실시예 4. 조직학 및 면역조직화학Example 4. Histology and Immunohistochemistry
실험 종료 시, 마우스의 무릎 관절을 4 ℃에서 >24시간 동안 10% 포름알데히드에 고정시키고, 2주 동안 PBS (pH 7.4) 중 0.5 메틸렌디아민테트라아세트산 (Methylenediaminetetraacetic acid (EDTA))에서 2주 동안 탈석회시킨 후 파라핀에 포매하였다. 다음으로, 파라핀 블록을 5 μm 구간으로 얇게 잘라 헤마톡실린과 에오신, 0.1% 사프라닌-O (s8884, Sigma-Aldrich, St Louis, MO, USA) 및 0.05 % 패스트그린 FCF (f7258, Sigma-Aldrich, St Louis, MO, USA)로 염색하였다.At the end of the experiment, the knee joints of mice were fixed in 10% formaldehyde for >24 h at 4°C and dehydrated in 0.5 Methylenediaminetetraacetic acid (EDTA) in PBS (pH 7.4) for 2 weeks. After being limed, it was embedded in paraffin. Next, the paraffin block was cut into 5 μm sections and incubated with hematoxylin and eosin, 0.1% Safranin-O (s8884, Sigma-Aldrich, St Louis, MO, USA) and 0.05% Fastgreen FCF (f7258, Sigma-Aldrich). Aldrich, St Louis, MO, USA).
관절 연골 파괴는 표준 OA(골관절염) 등급인 OARSI 등급 (0-6)을 이용하여 점수를 매겼으며, 경화증과 관절 연골 파괴는 사프라닌-O 염색을 통해 확인되었으며, OsteoMeasureXP (OsteoMetrics, Inc., Atlanta, GA, USA), Image-pro plus (v4.5, Media Cybernetics, Inc., Rockville, USA), Adobe photoshop (v9.0, San Jose, CA, USA) 및 Olympus DP72 charge-coupled device camera (v2.1, Olympus Corporation, Tokyo, Japan)을 사용하여 측정되었다.Articular cartilage destruction was scored using the standard OA (osteoarthritis) grading OARSI scale (0-6), and sclerosis and articular cartilage destruction were identified using Safranin-O staining and OsteoMeasureXP (OsteoMetrics, Inc., Atlanta, GA, USA), Image-pro plus (v4.5, Media Cybernetics, Inc., Rockville, USA), Adobe photoshop (v9.0, San Jose, CA, USA) and Olympus DP72 charge-coupled device camera ( v2.1, Olympus Corporation, Tokyo, Japan).
연골하골판 (the subchondral bone plate (SBP)) 두께를 측정하여 연골하골경화증을 결정하였다. 무릎 관절 절편을 1차 항-OSCAR 항체 (Cat# SC34235, Santa Cruz Biotechnology, Inc., Dallas, TX, USA and Biorbyt, LLC, St Louis, USA, 1:200 dilution)와 함께 4 ℃에서 밤새 인큐베이션하였다. Subchondral osteosclerosis was determined by measuring the thickness of the subchondral bone plate (SBP). Knee joint sections were incubated overnight at 4°C with primary anti-OSCAR antibody (Cat# SC34235, Santa Cruz Biotechnology, Inc., Dallas, TX, USA and Biorbyt, LLC, St Louis, USA, 1:200 dilution). .
면역 활성을 감지하기 위해 3,3'-diaminobenzidine peroxidase (DAB; horseradish peroxidase) 기질 감지 키트 (Vector Laboratories, Inc., Burlingame, CA, USA)를 사용하고, hematoxylin을 사용하여 대조 염색하였다. MMP3 (Cat# Ab53015, Abcam, Cambridge, MA, USA, 1:50 dilution), MMP13 (Cat# Ab51072, Abcam, 1:25 dilution), Aggrecan (Cat# Ab1031, Abcam 1:100 dilution), COL2A1 (Cat# MAB8887, Sigma-Aldrich, St Louis, MO, USA, 1:50 dilution), ADAMTS5 (Cat# GTX100332, Genetex, Irvine, CA, USA, 1:200 dilution), SOX9 (Cat# ab185230, Abcam 1:50 dilution), TGFβ(Cat# 3711s, Cell Signaling Technology, 1:25), p-smad2 (Cat# ab188334, Abcam 1:50 dilution) 및 p-smad3 (Cat# ab52903, Abcam 1:25 dilution)에 대한 항체를 사용하여 추가 면역 염색을 수행하였다.To detect immune activity, a 3,3'-diaminobenzidine peroxidase (DAB; horseradish peroxidase) substrate detection kit (Vector Laboratories, Inc., Burlingame, CA, USA) was used and counterstained using hematoxylin. MMP3 (Cat# Ab53015, Abcam, Cambridge, MA, USA, 1:50 dilution), MMP13 (Cat# Ab51072, Abcam, 1:25 dilution), Aggrecan (Cat# Ab1031, Abcam 1:100 dilution), COL2A1 (Cat # MAB8887, Sigma-Aldrich, St Louis, MO, USA, 1:50 dilution), ADAMTS5 (Cat# GTX100332, Genetex, Irvine, CA, USA, 1:200 dilution), SOX9 (Cat# ab185230, Abcam 1:50) dilution), TGFβ (Cat# 3711s, Cell Signaling Technology, 1:25), p-smad2 (Cat# ab188334, Abcam 1:50 dilution), and p-smad3 (Cat# ab52903, Abcam 1:25 dilution) Additional immunostaining was performed using .
관절 연골 세포 사멸은 TUNEL 분석과 Millipore의 키트 (Apoptosis Detection kit, Lot #2397039, Temecula, CA, USA)를 사용하여 결정되었다. 검체를 형광현미경으로 가시화하여 총 세포수 대비 세포사멸성 관절연골세포의 수를 계수하였다.Articular cartilage cell death was determined using the TUNEL assay and a kit from Millipore (Apoptosis Detection kit, Lot #2397039, Temecula, CA, USA). The specimen was visualized using a fluorescence microscope, and the number of apoptotic articular chondrocytes was counted compared to the total number of cells.
실시예 5. RNA 분리 및 정량적 실시간 PCR 수행Example 5. RNA isolation and quantitative real-time PCR performance
TRIzol 시약 (Invitrogen, Carlsbad, CA, USA)을 이용하여 1차 연골세포, 골수대식세포 (BMM) 및 골수중간엽줄기세포 (BMMSC)에서 총 RNA를 분리하거나 RNA Mini Kit (Life Technologies, Carlsbad, CA, USA)를 사용하여 마우스와 인간의 무릎 관절 조직에서 분리하고 역전사하여 상보적인 DNA (cDNA)는 제조업체의 지침에 따라 Superscript cDNA 합성 키트 (Invitrogen)를 사용하였다.Total RNA was isolated from primary chondrocytes, bone marrow macrophages (BMM), and bone marrow mesenchymal stem cells (BMMSC) using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) or RNA Mini Kit (Life Technologies, Carlsbad, CA). , USA) was used to isolate and reverse-transcribe complementary DNA (cDNA) from mouse and human knee joint tissues using the Superscript cDNA synthesis kit (Invitrogen) according to the manufacturer's instructions.
실시간 정량 PCR은 Step One Plus 실시간 PCR 기기 (Applied Biosystems, Foster City, CA, USA)에서 KAPA SYBR Green fast qPCR 키트 (Kapa Biosystems, Inc., Wilmington, MA, USA)를 사용하여 수행되었다. 샘플을 3중으로 분석하고, β을 하우스키핑 유전자로 사용하여 데이터를 정규화하였다. 프라이머의 전체 목록은 표 1에 나열되어 있다.Real-time quantitative PCR was performed using the KAPA SYBR Green fast qPCR kit (Kapa Biosystems, Inc., Wilmington, MA, USA) on a Step One Plus real-time PCR instrument (Applied Biosystems, Foster City, CA, USA). Samples were analyzed in triplicate, and data were normalized using β as a housekeeping gene. The full list of primers is listed in Table 1.
[표 1][Table 1]
Figure PCTKR2023015909-appb-img-000002
Figure PCTKR2023015909-appb-img-000002
실시예 6. 카스파제 분석 (Caspase assay)Example 6. Caspase assay
Caspase-3 및 caspase-8 활성은 caspase 비색 분석 키트 (Biovision Research Products, Milpitas, CA, USA)를 사용하여 결정되었다. 관절 연골세포 용해물을 37 ℃에서 2시간 동안 caspase-3 (DEVD-pNA) 또는 caspase-8 (IETD-pNA)에 대한 기질과 함께 인큐베이션하였다. 각 카스파제의 활성은 405 nm에서의 흡광도를 측정하여 결정하였다.Caspase-3 and caspase-8 activities were determined using the caspase colorimetric assay kit (Biovision Research Products, Milpitas, CA, USA). Articular chondrocyte lysates were incubated with substrates for caspase-3 (DEVD-pNA) or caspase-8 (IETD-pNA) for 2 hours at 37°C. The activity of each caspase was determined by measuring absorbance at 405 nm.
실시예 7. MTT 분석Example 7. MTT assay
1차 관절 연골세포는 OSC 콜라겐 펩타이드 (2 μg/ml) 및 10　ng/ml의 IL-1β의 존재 하에 48시간 동안 브리부딘으로 처리되거나 처리되지 않았다. 이후, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)를 각 웰의 배양 배지에 첨가하고, 샘플을 37 ℃에서 4시간 동안 인큐베이션하였다. 다음으로, 디메틸설폭사이드를 실온에서 10분 동안 각 웰에 첨가한 후, 570 nm의 광학 밀도에서 흡광도를 측정하였다.Primary articular chondrocytes were treated with or without brivudin for 48 hours in the presence of OSC collagen peptide (2 μg/ml) and 10 ng/ml of IL-1β. Afterwards, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added to the culture medium of each well, and the samples were incubated at 37°C for 4 hours. Next, dimethyl sulfoxide was added to each well for 10 minutes at room temperature, and then the absorbance was measured at an optical density of 570 nm.
실시예 8. 정량화 및 통계 분석Example 8. Quantification and statistical analysis
모든 데이터는 최소 4번의 독립적인 실험에서 수집되었다. 통계 분석은 두 표본 간의 차이를 분석하기 위해 Student's two-tailed t-test를 사용하여 수행되었다. 2개 이상의 샘플에 대한 분석은 일원 분산 분석 (ANOVA) 및 이원 분산 분석 (ANOVA)을 사용하여 수행한 후 유의미한 경우 쌍별 다중 비교를 수행하였다. 순서 등급 시스템을 사용하여 측정된 변수와 두 샘플의 비교를 기반으로 하는 데이터는 Sidak의 다중 비교 테스트를 사용하여 분석되었다.All data were collected from at least four independent experiments. Statistical analysis was performed using Student's two-tailed t -test to analyze differences between two samples. Analysis of more than two samples was performed using one-way analysis of variance (ANOVA) and two-way analysis of variance (ANOVA), followed by pairwise multiple comparisons when significant. Data based on comparisons of two samples with variables measured using an ordinal ranking system were analyzed using Sidak's multiple comparison test.
다중 비교는 Dunnett의 검정 또는 Tukey의 검정과 일원 분산 분석 ANOVA를 사용하여 수행되었다. 각 실험의 표본 크기는 미리 결정되지 않았다. P-값은 도면에 표시되며, 오차 막대는 모수 데이터의 경우 평균 (S.E.M)의 표준 오차를 나타내고, 비모수 데이터의 경우 계산된 95% 신뢰 구간을 나타낸다. 모든 그래프 및 통계 분석은 GraphPad Prism (v8.4.3, San Diego, CA, USA)을 사용하여 수행되었다.Multiple comparisons were performed using Dunnett's test or Tukey's test and one-way analysis of variance ANOVA. The sample size for each experiment was not predetermined. P-values are shown in the figures, and error bars represent the standard error of the mean (S.E.M.) for parametric data and the calculated 95% confidence interval for non-parametric data. All graphs and statistical analyzes were performed using GraphPad Prism (v8.4.3, San Diego, CA, USA).
실험예 1. 브리부딘 (brivudine)의 연골세포 내 OSCAR 억제 효과 확인Experimental Example 1. Confirmation of the OSCAR inhibitory effect of brivudine in chondrocytes
관절의 연골조직에는 혈관, 림프관 및 신경이 분포하고 있지 않으므로, 손상에 대한 세포의 이동 및 재생 능력이 제한적이며, 세포외 기질 (extracellular matrix; ECM)과 연골세포의 상호작용 및 연골세포 하류 신호전달 과정에 관하여 확인이 필요하다. 따라서, 연골세포 표면에 발현되고 있는 수용체의 신호전달에 따른 연골세포의 동화 및 이화 작용, 이로부터 조절되는 전사인자와 관련한 실험을 수행하였다. 즉, OSCAR 수용체와 콜라겐의 결합을 억제하는 경쟁적 저해제로서 브리부딘 (brivudine; EK2) 유효물질에 대하여 연골세포 내에서 OSCAR 억제 효과 및 작용점을 규명하기 위해 사전적으로 관절 연골세포에서 아데노 부속 바이러스를 통한 OSCAR 과발현 실험을 수행하였다.Since blood vessels, lymphatic vessels, and nerves are not distributed in the cartilage tissue of joints, the migration and regenerative ability of cells in response to damage is limited, and the interaction between extracellular matrix (ECM) and chondrocytes and chondrocyte downstream signaling Confirmation is needed regarding the process. Therefore, experiments were conducted on the anabolic and catabolic effects of chondrocytes according to the signaling of receptors expressed on the surface of chondrocytes, and the transcription factors regulated therefrom. In other words, in order to identify the inhibitory effect and point of action of OSCAR within chondrocytes for the active substance brivudine (EK2), which is a competitive inhibitor that inhibits the binding of OSCAR receptors to collagen, OSCAR was conducted through adeno-associated virus in articular chondrocytes in advance. Overexpression experiments were performed.
1-1. 1차 연골세포 추출 및 Ad-OSCAR 바이러스 감염1-1. Primary chondrocyte extraction and Ad-OSCAR virus infection
1차 연골세포는 생후 4~5일령 정도의 ICR 마우스의 대퇴 아지 및 경골 원판으로부터 세포를 분리하여 준비하였다. 이후, 10% 소 태아 혈청 (fetal bovine serum; FBS), 100 units/ml 페니실린 (penicillin) 및 100 μg/ml 스트렙토마이신 (streptomycin)으로 보충된 DMEM에서 배양하고, 히아루론산의 처리 및 아데노 부속 OSCAR 바이러스의 감염 실험을 통해 관절 연골세포 내에서 OSCAR를 과발현 시켰다.Primary chondrocytes were prepared by isolating cells from the femoral limb and tibial disc of ICR mice about 4 to 5 days old. Thereafter, cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 100 μg/ml streptomycin, treated with hyaluronic acid, and inoculated with adeno-attached OSCAR virus. Through infection experiments, OSCAR was overexpressed in articular chondrocytes.
1-2. OSCAR 저해 유효물질 5종의 OSCAR 억제 효과 확인1-2. Confirmation of OSCAR inhibition effect of 5 types of OSCAR inhibitory substances
상기 실시예 1의 스크리닝 결과로 도출된 상위 5종의 유효물질을 OSCAR가 과발현된 관절 연골세포에 처리하여 OSCAR의 mRNA 발현이 저해된 수준을 관찰하였다 (도 3).Articular chondrocytes overexpressing OSCAR were treated with the top five effective substances derived from the screening results of Example 1, and the level of inhibition of OSCAR mRNA expression was observed (FIG. 3).
그 결과, 도 3에서 확인되는 바와 같이, Top 4 물질을 제외한 나머지 4종 (Top 1, 2, 3, 및 5)에서 유의하게 OSCAR mRNA 발현이 억제되는 것을 확인하였다. 이 때, 유효 농도는 각각 5 내지 20 μM이다. 여기서, Top 3 물질이 브리부딘 (brivudine; EK2)이다.As a result, as seen in Figure 3, it was confirmed that OSCAR mRNA expression was significantly suppressed in the remaining four substances (Top 1, 2, 3, and 5) excluding the Top 4 substances. At this time, the effective concentration is 5 to 20 μM, respectively. Here, the top 3 substances are brivudine (EK2).
이를 통해, 브리부딘이 OSCAR 저해 유효물질로서, OSCAR 억제에 우수한 효과가 있음을 나타낸다.This shows that brivudin is an effective OSCAR inhibitory substance and has an excellent effect on OSCAR inhibition.
실험예 2. 브리부딘의 OSCAR 신호전달 조절Experimental Example 2. Regulation of OSCAR signaling by brivudin
2-1. 연골세포 내 OSCAR 신호전달 체계 활성화2-1. Activation of OSCAR signaling system in chondrocytes
OSCAR의 리간드 콜라겐 (OSCAR-binding Collagen; OSC)으로 사전 코팅된 배양접시에 1차 연골세포를 배양하여 OSCAR 신호전달 체계를 활성화하였다. 이후, 브리부딘 (brivudine), 즉 EK2 물질을 처리하여 연골세포 내 OSCAR 저해제로서 세포 내 작용점 연구를 수행하였다.The OSCAR signaling system was activated by culturing primary chondrocytes on a culture dish pre-coated with OSCAR-binding Collagen (OSC). Afterwards, brivudine, that is, an EK2 substance, was treated to study the intracellular point of action as an OSCAR inhibitor in chondrocytes.
그 결과, 브리부딘 처리를 통해 연골세포 내 OSCAR mRNA 발현이 감소하는 것을 확인하였다 (도 4).As a result, it was confirmed that OSCAR mRNA expression in chondrocytes decreased through brivudin treatment (Figure 4).
2-2. 염증활성모델에서 브리부딘의 연골퇴행마커(catabolic marker) 저해2-2. Bribudine inhibits cartilage degeneration markers (catabolic markers) in an inflammatory activity model.
마우스의 관절에서 추출한 1차 연골세포에 염증성 사이토카인 IL-1β (interleukin-1β) 10 ng/ml을 처리하여 염증반응 신호체계를 활성화한 후, 브리부딘을 처리하였다.Primary chondrocytes extracted from mouse joints were treated with 10 ng/ml of the inflammatory cytokine IL-1β (interleukin-1β) to activate the inflammatory response signaling system, and then treated with brivudin.
염증이 활성화되면 세포외 기질 분해효소 (matrix metalloproteinase)의 분비가 증가하는데, 해당 효소는 연골세포를 둘러싸고 있는 세포외 기질을 직접적으로 분해함으로써 연골조직의 점진적인 퇴행을 야기한다. 이와 같이 염증으로 연골퇴행마커 (catabolic marker)인 MMP3 및 MMP13이 활성화된 모델에 브리부딘 물질을 처리하고 연골퇴행마커들의 mRNA 발현 변화를 측정하였다.When inflammation is activated, the secretion of extracellular matrix metalloproteinase increases, and this enzyme directly decomposes the extracellular matrix surrounding cartilage cells, causing gradual degeneration of cartilage tissue. In this way, a model in which cartilage degeneration markers (catabolic markers) MMP3 and MMP13 were activated due to inflammation was treated with brivudine and changes in mRNA expression of cartilage degeneration markers were measured.
그 결과, 브리부딘이 연골퇴행마커인 MMP3 및 MMP13의 발현량을 유의하게 감소시킴을 확인하였다 (도 4). 이는, 브리부딘이 연골사멸 신호전달을 조절하고 있다는 것을 시사한다.As a result, it was confirmed that brivudin significantly reduced the expression levels of cartilage degeneration markers, MMP3 and MMP13 (Figure 4). This suggests that brivudin regulates cartilage death signaling.
2-3.2-3. 염증활성모델에서 브리부딘의 연골재생마커(anabolic marker) 촉진Bribudine promotes cartilage regeneration markers (anabolic markers) in an inflammatory activity model.
상기 실험예 2-2와 동일한 염증 활성 모델에서, 브리부딘을 처리하여 연골의 2형 콜라겐 (COL2A1) 및 연골 재생 유전자 마커 (SOX9)의 mRNA 발현이 증가하는 것을 확인하였다 (도 4). In the same inflammatory activity model as Experimental Example 2-2, it was confirmed that treatment with brivudin increased the mRNA expression of cartilage type 2 collagen (COL2A1) and cartilage regeneration gene marker (SOX9) (FIG. 4).
염증이 활성화되면 연골재생마커는 발현이 억제되는데, 브리부딘은 유의하게 상기 마커의 발현을 증가시킴을 확인하였다. 이를 통해, 연골 형성 및 발달에 핵심적인 역할을 하는 전사인자 SOX9의 조절이 브리부딘을 통해 이루어짐을 시사한다.When inflammation is activated, the expression of cartilage regeneration markers is suppressed, and brivudin was confirmed to significantly increase the expression of these markers. This suggests that the regulation of SOX9, a transcription factor that plays a key role in cartilage formation and development, is achieved through brivudin.
실험예 3. 브리부딘의 연골세포 분화 촉진Experimental Example 3. Bribudin promotes chondrocyte differentiation
골수 유래 중간엽 줄기세포 (bone marrow mesenchymal stem cell; BMMSC)에 연골재생인자 (chondrogenic factor)를 2주간 처리하면 중간엽 줄기세포가 하류 연골세포, 조골세포, 지방세포 중 연골세포로 분화하게 된다 (도 5a). 이 때 Ad-OSCAR를 함께 처리하면 연골세포 분화가 저해된다.When bone marrow mesenchymal stem cells (BMMSC) are treated with chondrogenic factors for 2 weeks, the mesenchymal stem cells differentiate into chondrocytes among downstream chondrocytes, osteoblasts, and adipocytes ( Figure 5a). At this time, when treated with Ad-OSCAR, chondrocyte differentiation is inhibited.
Ad-OSCAR 처리로 연골 분화가 억제된 세포에 다시 2주 동안 브리부딘, 즉 EK2 물질을 처리한 결과, 분화능이 회복되고 연골세포로 분화하는 것을 확인하였다 (도 5b).When cells whose cartilage differentiation was inhibited by Ad-OSCAR treatment were treated with brivudin, an EK2 substance, for another 2 weeks, it was confirmed that their differentiation capacity was restored and they differentiated into chondrocytes (FIG. 5b).
이를 통해, 브리부딘은 줄기세포로부터 연골 분화 제어 효과가 있으며, 특히 연골 세포로의 분화 촉진 효과가 있음을 나타낸다.This shows that brivudin has an effect in controlling cartilage differentiation from stem cells and, in particular, has an effect in promoting differentiation into chondrocytes.
실험예 4. 브리부딘의 연골세포의 생존 조절Experimental Example 4. Control of survival of chondrocytes by brivudin
브리부딘 물질이 연골세포의 생존 (cell viability)에 영향을 미치는지 확인하기 위해 CCK8 assay를 수행하였다. 먼저, OSCAR 리간드 콜라겐 (OSCAR-binding collagen; OSC)을 사전에 코팅해 둔 플레이트에 1차 연골세포를 배양하여 OSCAR 신호전달 체계를 활성화하였다. 이후, 연골세포를 36시간 동안 배양한 후, 염증성 사이토카인 IL-1β를 처리하여 염증 반응 및 연골세포 사멸 신호체계를 활성화하였다.CCK8 assay was performed to determine whether the brivudin substance affects the survival (cell viability) of chondrocytes. First, the OSCAR signaling system was activated by culturing primary chondrocytes on a plate pre-coated with OSCAR-binding collagen (OSC). Afterwards, the chondrocytes were cultured for 36 hours and then treated with the inflammatory cytokine IL-1β to activate the inflammatory response and chondrocyte death signaling system.
그리고 브리부딘, 즉 EK2의 유효농도를 5 μM, 10 μM의 2개로 나누어 연골세포에 처리하였다. 추가 48시간 배양 후에 CCK8 assay를 이용하여 세포 생존을 확인하였다. 그 결과, 브리부딘 10 μM 농도에서 유의하게 연골 세포가 회복되고 생존함을 확인하였다 (도 6).And the effective concentration of brivudin, that is, EK2, was divided into two, 5 μM and 10 μM, and treated with chondrocytes. After an additional 48 hours of culture, cell survival was confirmed using the CCK8 assay. As a result, it was confirmed that chondrocytes were significantly recovered and survived at a concentration of 10 μM of brivudin (FIG. 6).
이를 통해, 세포사멸 신호체계에서도 브리부딘 물질이 연골세포 재생에 유효함을 시사한다.This suggests that brivudin is effective in cartilage cell regeneration even in the cell death signaling system.
실험예 5. 브리부딘의 골관절염 (osteoarthritis; OA) 치료효과Experimental Example 5. Treatment effect of brivudin on osteoarthritis (OA)
5-1. 브리부딘의 골관절염 동물모델에서 연골조직 재생 효과 확인5-1. Confirmation of cartilage tissue regeneration effect of Bribudin in osteoarthritis animal model
C57BL/6 마우스에 DMM 수술로 골관절염 (osteoarthritis; OA)을 유도하여 발병하는 동안 브리부딘 물질을 무릎강 내 2가지 농도 즉, 0.5 mg/kg 및 2 mg/kg으로 주사하였다.While osteoarthritis (OA) was induced in C57BL/6 mice by DMM surgery, brivudine was injected into the knee cavity at two concentrations, that is, 0.5 mg/kg and 2 mg/kg.
골관절염의 발병 완화를 확인하기 위해, i) 연골 퇴행 정도를 정량하는 지표인 OARSI grade, ii) OA 판단법 중 하나인 골극 형성 (osteophyte formation) 정도, iii) 연골 하골 (subchondral boe plate; SBP)의 두께 측정, iv) 활액막염 (synovitis) 진행도 및 v) 유리 연골 (hyaline cartilage) 대비 석회화 연골 (calcified cartilage)의 비율을 측정하였다. To confirm the relief of osteoarthritis, i) OARSI grade, which is an indicator for quantifying the degree of cartilage degeneration, ii) the degree of osteophyte formation, which is one of the methods for determining OA, and iii) the thickness of subchondral bone plate (SBP). Measurements, iv) synovitis progression, and v) the ratio of calcified cartilage to hyaline cartilage were measured.
그 결과, 브리부딘, 즉 EK2 물질을 무릎 관절강 내로 주입하는 경우, DMM 실시 후 비히클 (vehicle; Veh)만을 전달한 양성 대조군 (positive control) 그룹에 대비하여, 골관절염 증상이 현저하게 완화됨을 확인하였다 (도 7).As a result, it was confirmed that when brivudin, or EK2 substance, was injected into the knee joint space, osteoarthritis symptoms were significantly alleviated compared to the positive control group that only delivered vehicle (Veh) after DMM (Figure 7).
이를 통해, 브리부딘의 무릎 관절강 내 주사를 통해 이미 일어난 골관절염이 회복되고 연골이 재생되는 효과가 있음을 나타낸다.This shows that intra-articular injection of Bribudin has the effect of recovering osteoarthritis that has already occurred and regenerating cartilage.
5-2. 연골 퇴행 후 재생 효과 확인5-2. Confirmation of regenerative effect after cartilage degeneration
본 발명의 브리부딘, 즉 EK2 물질은 in vivo 실험에서 마우스에게 DMM 수술을 일으켜 골관절염 (OA)을 유발한 뒤 바로 관절내 주사 (intra-articular injection; IA injection)하지 않고, 총 8주의 실험기간 중에서 후반부 4주차부터 관절내 주사를 하였다.Bribudine, the EK2 substance of the present invention, is not injected immediately after intra-articular injection (IA injection) after DMM surgery in mice to induce osteoarthritis (OA) in an in vivo experiment, but is administered within a total of 8 weeks of experiment. In the second half, starting from the 4th week, intra-articular injections were administered.
이는 골관절염 유발 초기단계부터 유효 약물이 주입되어 질병의 예방적 측면보다는, 이미 중간단계 이상 수준으로 골관절염이 유발되어서 어느 정도 연골 퇴행이 진행된 상태에서 약물을 투입하여 질병의 치료적 측면을 확인하기 위한 것이다.This is to check the therapeutic aspect of the disease by injecting the drug when the osteoarthritis has already been induced to an intermediate level or higher and cartilage degeneration has progressed to some extent, rather than the preventive aspect of the disease by injecting an effective drug from the early stage of inducing osteoarthritis. .
그 결과, 브리부딘, 즉 EK2 물질을 후반부 4주차부터 1회 관절내 주사한 경우에도, moderate OA 단계의 골관절염을 역행하는 것을 확인하였다. 이는, 골관절염 유발 전체 기간 동안 약물 주사를 해야하는 다른 골관절염 치료제 유효물질과 대비하여, 후반부 총 4회의 관절내 주사만으로도 연골 재생을 확인한 것이므로, 후기 치료만으로 연골재생이 가능함을 시사한다.As a result, it was confirmed that even when intra-articular injection of brivudin, or EK2 substance, was administered once from the fourth week of the latter half, osteoarthritis in the moderate OA stage was reversed. This suggests that cartilage regeneration is possible only with late-stage treatment, as cartilage regeneration was confirmed with only four intra-articular injections in the second half, compared to other active substances for the treatment of osteoarthritis that require drug injections during the entire period of inducing osteoarthritis.
본 발명의 브리부딘을 유효성분으로 포함하는 조성물은 OSCAR 신호전달 체계를 조절하고, 구체적으로 상기 조성물은 OSCAR mRNA 발현을 감소시키고 염증 완화, 연골세포의 분화 및 재생 촉진을 통해 골 대사성 질환을 포함하는 OSCAR 유도 질환 치료에 유용하게 사용될 수 있을 것이다.The composition containing brivudin as an active ingredient of the present invention regulates the OSCAR signaling system, and specifically, the composition reduces OSCAR mRNA expression, alleviates inflammation, and promotes differentiation and regeneration of chondrocytes to treat bone metabolic diseases. It may be useful in treating OSCAR-induced diseases.
이상, 첨부된 도면을 참조로 하여 본 발명의 실시예를 설명하였지만, 본 발명이 속하는 기술분야의 통상의 기술자는 본 발명이 그 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 그러므로, 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며, 제한적이 아닌 것으로 이해해야만 한다.Above, embodiments of the present invention have been described with reference to the attached drawings, but those skilled in the art will understand that the present invention can be implemented in other specific forms without changing its technical idea or essential features. You will be able to understand it. Therefore, the embodiments described above should be understood in all respects as illustrative and not restrictive.

Claims (15)

  1. 하기 화학식 1로 표시되는 브리부딘 (brivudine) 또는 이의 약제학적으로 허용가능한 염을 유효성분으로 포함하는, 골관절염의 예방 또는 치료용 약학적 조성물.A pharmaceutical composition for preventing or treating osteoarthritis, comprising brivudine or a pharmaceutically acceptable salt thereof represented by the following formula (1) as an active ingredient.
    [화학식 1][Formula 1]
    Figure PCTKR2023015909-appb-img-000003
    Figure PCTKR2023015909-appb-img-000003
  2. 제1항에 있어서,According to paragraph 1,
    상기 조성물은 오스카 (OSCAR) 저해 활성을 가지는 것을 특징으로 하는, 약학적 조성물.A pharmaceutical composition, characterized in that the composition has OSCAR inhibitory activity.
  3. 제1항에 있어서,According to paragraph 1,
    상기 조성물은 연골퇴행마커의 mRNA 발현을 감소시키는 것을 특징으로 하는, 약학적 조성물.A pharmaceutical composition, characterized in that the composition reduces mRNA expression of cartilage degeneration markers.
  4. 제3항에 있어서,According to paragraph 3,
    상기 연골퇴행마커는 MMP3 또는 MMP13인 것을 특징으로 하는, 약학적 조성물.A pharmaceutical composition, wherein the cartilage degeneration marker is MMP3 or MMP13.
  5. 제1항에 있어서,According to paragraph 1,
    상기 조성물은 연골재생마커의 발현을 증가시키는 것을 특징으로 하는, 약학적 조성물.A pharmaceutical composition, characterized in that the composition increases the expression of cartilage regeneration markers.
  6. 제5항에 있어서,According to clause 5,
    상기 연골재생마커는 COL2A1 또는 SOX9인 것을 특징으로 하는, 약학적 조성물.A pharmaceutical composition, wherein the cartilage regeneration marker is COL2A1 or SOX9.
  7. 제1항에 있어서,According to paragraph 1,
    상기 조성물은 연골 세포의 생존율을 증가시키는 것을 특징으로 하는, 약학적 조성물.A pharmaceutical composition, characterized in that the composition increases the survival rate of cartilage cells.
  8. 제1항에 있어서,According to paragraph 1,
    상기 조성물은 연골 세포의 분화를 증가시키는 것을 특징으로 하는, 약학적 조성물.A pharmaceutical composition, characterized in that the composition increases differentiation of chondrocytes.
  9. 제1항에 있어서,According to paragraph 1,
    상기 조성물은 연골 조직의 재생을 증가시키는 것을 특징으로 하는, 약학적 조성물.A pharmaceutical composition, characterized in that the composition increases the regeneration of cartilage tissue.
  10. 제1항에 있어서,According to paragraph 1,
    상기 조성물은 국부 투여 (local administration), 국소 투여 (topical administration) 및 주사로 구성된 군으로부터 선택된 어느 하나의 방법으로 투여되는 것을 특징으로 하는, 약학적 조성물.A pharmaceutical composition, characterized in that the composition is administered by any one method selected from the group consisting of local administration, topical administration, and injection.
  11. 제10항에 있어서,According to clause 10,
    상기 주사에 의한 투여는 관절 내 주사에 의한 것을 특징으로 하는, 약학적 조성물.A pharmaceutical composition, wherein the administration by injection is by intra-articular injection.
  12. 제1항의 조성물을 골관절염이 의심되는 인간을 제외한 대상체에 투여하는 단계를 포함하는, 골관절염의 치료 방법.A method of treating osteoarthritis, comprising administering the composition of claim 1 to a subject other than a human suspected of having osteoarthritis.
  13. 하기 화학식 1로 표시되는 브리부딘 (brivudine) 또는 이의 식품학적으로 허용가능한 염을 유효성분으로 포함하는, 골관절염의 예방 또는 개선용 식품 조성물.A food composition for preventing or improving osteoarthritis, comprising brivudine or a foodologically acceptable salt thereof represented by the following formula (1) as an active ingredient.
    [화학식 1][Formula 1]
    Figure PCTKR2023015909-appb-img-000004
    Figure PCTKR2023015909-appb-img-000004
  14. 하기 화학식 1로 표시되는 브리부딘 (brivudine) 또는 이의 약제학적으로 허용가능한 염을 유효성분으로 포함하는, 골관절염의 예방 또는 개선용 의약외품 조성물.A quasi-drug composition for preventing or improving osteoarthritis, comprising brivudine or a pharmaceutically acceptable salt thereof represented by the following formula (1) as an active ingredient.
    [화학식 1][Formula 1]
    Figure PCTKR2023015909-appb-img-000005
    Figure PCTKR2023015909-appb-img-000005
  15. 하기 화학식 1로 표시되는 브리부딘 (brivudine) 또는 이의 사료학적으로 허용가능한 염을 유효성분으로 포함하는, 골관절염의 예방 또는 개선용 사료 첨가제 조성물.A feed additive composition for preventing or improving osteoarthritis, comprising brivudine or a feed-chemically acceptable salt thereof represented by the following formula (1) as an active ingredient.
    [화학식 1][Formula 1]
    Figure PCTKR2023015909-appb-img-000006
    Figure PCTKR2023015909-appb-img-000006
PCT/KR2023/015909 2022-10-19 2023-10-16 Composition for preventing or treating oscar-induced diseases, containing brivudin as active ingredient WO2024085558A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020220135186A KR102545956B1 (en) 2022-10-19 2022-10-19 Composition for preventing or treating OSCAR-induced diseases comprising brivudine as an active ingredient
KR10-2022-0135186 2022-10-19

Publications (1)

Publication Number Publication Date
WO2024085558A1 true WO2024085558A1 (en) 2024-04-25

Family

ID=86988914

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/015909 WO2024085558A1 (en) 2022-10-19 2023-10-16 Composition for preventing or treating oscar-induced diseases, containing brivudin as active ingredient

Country Status (2)

Country Link
KR (1) KR102545956B1 (en)
WO (1) WO2024085558A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102545956B1 (en) * 2022-10-19 2023-06-22 주식회사 카이팜 Composition for preventing or treating OSCAR-induced diseases comprising brivudine as an active ingredient

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037753A1 (en) * 1998-01-23 1999-07-29 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
WO2002056832A2 (en) * 2001-01-19 2002-07-25 Newbiotics, Inc. Methods to treat autoimmune and inflammatory conditions
KR20220108398A (en) * 2021-01-27 2022-08-03 전남대학교산학협력단 Pharmaceutical composition for the prevention or treatment of osteoarthritis by inhibiting the absorption of cholesterol in the body containing ezetimibe as an active ingredient
KR20220137433A (en) * 2021-04-02 2022-10-12 한국과학기술연구원 Pharmaceutical composition for the prevention or treatment of osteoarthritis comprising schisandrol A, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient
KR20220137432A (en) * 2021-04-02 2022-10-12 한국과학기술연구원 Pharmaceutical composition for the prevention or treatment of osteoarthritis comprising optusifolin, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient
KR102545956B1 (en) * 2022-10-19 2023-06-22 주식회사 카이팜 Composition for preventing or treating OSCAR-induced diseases comprising brivudine as an active ingredient

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037753A1 (en) * 1998-01-23 1999-07-29 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
WO2002056832A2 (en) * 2001-01-19 2002-07-25 Newbiotics, Inc. Methods to treat autoimmune and inflammatory conditions
KR20220108398A (en) * 2021-01-27 2022-08-03 전남대학교산학협력단 Pharmaceutical composition for the prevention or treatment of osteoarthritis by inhibiting the absorption of cholesterol in the body containing ezetimibe as an active ingredient
KR20220137433A (en) * 2021-04-02 2022-10-12 한국과학기술연구원 Pharmaceutical composition for the prevention or treatment of osteoarthritis comprising schisandrol A, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient
KR20220137432A (en) * 2021-04-02 2022-10-12 한국과학기술연구원 Pharmaceutical composition for the prevention or treatment of osteoarthritis comprising optusifolin, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient
KR102545956B1 (en) * 2022-10-19 2023-06-22 주식회사 카이팜 Composition for preventing or treating OSCAR-induced diseases comprising brivudine as an active ingredient

Also Published As

Publication number Publication date
KR102545956B1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
WO2024085558A1 (en) Composition for preventing or treating oscar-induced diseases, containing brivudin as active ingredient
WO2024085557A1 (en) Composition for preventing or treating oscar-induced diseases, comprising adefovir as active ingredient
JP2001503060A (en) Integrin antagonist
JP2015530378A (en) DDR2 inhibitors for the treatment of osteoarthritis
WO2018135719A1 (en) Composition for preventing or treating osteoarthritis containing sialyllactose or salt thereof as active ingredient
EP3790861A1 (en) Senolytic compositions and uses thereof
CA3194377A1 (en) Bioactive collagen peptides, method of production thereof, and use thereof
WO2011025086A1 (en) Pharmaceutical composition for preventing or treating rheumatoid arthritis, containing rebamipide
MXPA04001868A (en) Use of annellated pyrrole compounds in the treatment of articular cartilage or subchondral bone degeneration.
CN104955806B (en) The substituted carboxylic acid derivative as polyprotein xylanase inhibitor for treating osteoarthritis
WO2023027317A1 (en) Composition for treating muscle loss-related diseases comprising exosomes derived from tonsil mesenchymal stem cells
WO2019209061A1 (en) Bone growth-promoting composition comprising allium fistulosum linn as active ingredient
KR101752697B1 (en) Composition for Treating or Preventing Pancreatitis Comprising Naphthoquinone-based Compounds
WO2016163818A2 (en) Pharmaceutical composition for preventing or treating arthritis or inflammatory disease containing 2-methoxy-4-(3-(4-methoxyphenyl)propyl-1-en-1-yl)phenol as active ingredient
WO2022050803A1 (en) Metastasis-inhibiting composition of novel methylsulfonamide derivative compound
WO2021246755A1 (en) Composition, for preventing, alleviating or treating metabolic disease, comprising phospholipase d2 inhibitor
EP0585371B1 (en) Aromatic oligomeric compounds useful as mimics of bioactive macromolecules
CN104619326A (en) Therapeutic agent for systemic bone disease and use thereof
WO2021040416A1 (en) Pharmaceutical composition, for preventing or treating bone loss induced by metabolic bone diseases, comprising artemisia scoparia extract as active ingredient
WO2020130120A1 (en) Cancer metastasis inhibitor
WO2022119076A1 (en) Fusion protein including glp-1 receptor agonist and anti-oscar antibody, and use thereof
WO2020246671A1 (en) Composition for promoting bone growth including carrot leaf as active ingredient
WO2019045451A1 (en) Cartilage regeneration composition containing hapln1 as active ingredient
WO2023008978A1 (en) Sncg-targeting composition for treating or diagnosing degenerative disease
WO2019208914A1 (en) Composition comprising portulaca oleracea l. as effective ingredient for promoting bone growth